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GLOSSARY 
 
FO   Flag-Omomyc 
DOX   Doxycycline 
GSC  Glioblastoma Cancer Stem Cell 
GFP   Green Fluorescent Protein 
TRE  Tetracycline Responsive Element 
SOX2  SRY-box 2 
CCND1    Cyclin D1 
PTEN  Phosphatase And Tensin Homolog 
NCL  Nucleolin 
ODC  Ornithine decarboxylase 
HDAC  Histone deacetylase 
DUSP10 Dual-specificity phosphatase 
OLIG2 Oligodendrocyte transcription factor 2 
KDM1A Lysine Demethylase 1A 
RCOR2 REST Corepressor 2 
TF  Transcription Factor 
ChIP-seq Chromatin Immunoprecipitation sequencing 
qChIP  quantitative Chromatin Immunoprecipitation 
E-boxes Enhancer boxes 
PI   Propidium Iodide 
FITC  Fluorescein isothiocyanate 
TSS  Transcriptional Start Site 
TTS  Transcriptional Termination Site 
FPKM Fragments Per Kilobase of gene Million mapped 
reads 
RPKM Reads Per Kilobase of gene per Million mapped 
reads 
GSEA Gene Set Enrichment Analysis 
MsigDB Molecular signature database 
GO Gene Ontology 
CTD Carbossi-Terminal Domain 
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PRMT5 Protein Arginine Methyl Transferase 5 
GBM Glioblastoma 
FC Fold Change 
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SUMMARY 
The involvement of Myc in a wide range of molecular functions 
makes it, probably, the most studied transcription factor for 30 
years. Myc deregulation is common in at least 70% of human 
tumors and gives rise to a wide variety of oncogenic phenotypes, 
including breast, lung, cervical, ovarian and brain cancer. 
Therefore, our primary interest was to interfere with Myc 
function in Glioblastoma Stem Cells (GSCs) and Burkitt’s 
lymphoma cells, using a small peptide, named Omomyc. It is a 
Myc-bHLH mutant with outstanding capabilities to inhibit 
several types of human cancers. Omomyc displayed a significant 
impact on tumoral behavior in both model systems. This occurs 
because Omomyc replaces Myc at promoters and disrupts Myc 
protein network (Savino et al., 2011), affecting the expression of 
all those key genes - Myc target and not - directly involved in 
tumorigenesis. Furthermore, we found that Myc and Omomyc 
interact with the Protein Arginine Methyltransferase 5 (PRMT5) 
(Mongiardi et al. 2015), which catalyses the symmetrical di-
methylation of RNA polymerase II (RNAPII) at R1810, allowing 
proper termination and splicing of transcripts (Zhao et al., 2016). 
Myc regulates many aspects of transcription by RNAPII, as 
activation, pause release and elongation, but its role in 
termination is unknown. We found that Myc overexpression 
strongly increases symmetrical RNAPII arginine di-methylation 
(R1810me2s), while the concomitant expression of Omomyc 
counteracts this capacity. In addition, Omomyc expression 
modulates the RNAPII amount at Termination Transcription sites 
(TTSs) versus Transcription Start Sites (TSSs) in several genes.  
Altogether, these findings suggest that Myc modulates 
transcription termination through R1810me2s-RNAPII. 
Therefore, Myc overexpression may deregulate this process by 
influencing RNAP II arginine di-methylation levels, contributing 
to tumorigenesis. In this regard, Omomyc may fine-tune the 
expression of a variety of genes altered by Myc in cancer, 
affecting the PRMT5/Myc/RNAPII-R1810me2s axis.  
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Introduction 
1. Myc 
 
1.1 Structure of c-Myc. myc is a family of three related gene 
products (c-Myc, n-Myc, and l-Myc; in this thesis, Myc will refer 
to c-Myc). The myc gene was first identified as the transforming 
agent within chicken retroviruses (Sheiness et al., 1978). In the 
human genome, c-myc localizes to human chromosome 8q24, it 
contains three exons which encode a translation product of 439 
amino acids with a molecular weight of 64-kDa. The sequence of 
the Myc protein consists of two independent, functional and 
highly conserved polypeptide regions: a N-terminal 
transactivating domain and a C-terminal DNA binding segment. 
The transcriptional activation domain (TAD) contains two 
conserved regions known as Myc boxes (MBI and MBII). MBI 
box is involved in transcriptional activation in some context. In 
particular, MBI is the first contact point with P-TEFb, a cyclin 
CDK-complex that phosphorylates RNA polymerase II 
(RNAPII), stimulating transcriptional elongation (Rahl et al., 
2010). MBII is essential for Myc ability to promote cellular 
transformation, to drive tumorigenesis, to activate and repress 
transcription of the majority of Myc targets; it also regulates Myc 
protein turnover. Further, Myc architecture has a middle region 
rich in proline, glutamic acid, serine and threonine residues 
(PEST), followed by two other conserved boxes (MBIII and 
MBIV), and a nuclear localization sequence. Myc MBIII box is 
involved in transcriptional repression by recruitment of histone 
deacetylase 3 (HDAC3), while MBIV seems to be required for 
the pro-apoptotic Myc function. Finally, a 100-amino-acid 
carboxyterminal region contains the basic helix-loop-helix-
leucine zipper (bHLH-LZ) domain which mediates the 
heterodimerization with a small bHLH-LZ protein named Max 
(Fig. 1). This interaction is absolutely necessary to form a stable 
Myc-Max heterodimer able to contact directly specific DNA 
sequences called “Enhancer boxes” (E-boxes) to stimulate 
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transcription. Indeed, full-length Myc alone is unable to bind 
DNA (Grandori et al., 2000). Besides Myc-Max also Max-Max 
homodimers bind E-boxes (Dang et al., 1999; Nair et al., 2006; 
Tansey 2014). Although many functions of Myc appears to be 
dependent on its interaction with Max, there are considerable 
evidences that Myc retains some activity even without Max 
(Hopewell et al., 1995). Among the many identified Myc-
interacting proteins, only a few exclusively bind to Myc alone. 
The transcription factor YY1, which usually inhibits Myc-Max 
activity, can also interact with Myc. Myc alone interferes with 
p21-PCNA interaction during DNA replication, while p21 
inhibits Myc-Max transcriptional activation. Moreover, Myc was 
reported to associate with replication proteins and to localize to 
the origins of replication whereas Max was found at this level 
only at the sub-stoichiometric amount (Dominguez-Sola et al., 
2007; Gallant and Steiger 2009). Finally, a cleaved, cytoplasmic, 
form of Myc, named Myc-nick, is able to trigger tumor migration 
and metastasis independently of its transcriptional function 
(Conacci-Sorrell et al., 2010, 2014).  
 
 
 
Fig. 1 - Myc-Max heterodimer. A. The diagram depicts Myc and Max protein 
structure with their major domains (modified by Dang et al., 1999). B. Crystal 
structure of Myc/Max bHLH regions bound to the E-box. (Tansey 2014).  
 
A B 
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1.2 The Myc/Max/Mad network: a matter of balance in the 
cellular milieu. The heterodimerization of Myc with Max plays 
a fundamental role in proliferation, transformation, and apoptosis 
processes. Max has a short half-life but it is stable and 
constitutively expressed also in the absence of Myc, suggesting 
that Max activity is largely dependent on the abundance of Max-
associated transcription factors. Max homodimers may block 
Myc biological activity, probably through competition for the E-
box-binding sites. Other bHLH-LZ Max interactors are Mad1-4 
(Mad1, Mxi1, Mad3, and Mad4), Mnt and Mga (Fig. 2). These 
proteins are characterized by some Myc properties: a) weak 
homodimerization and DNA-binding capacities; b) efficient 
heterodimerization with Max and consequent binding to the E-
boxes; c) interference with Myc-Max activity. Specifically, 
Mad1, Mxi1 and related members constitute a family of 
transcriptional repressors at the same Myc-Max binding sites. A 
competition between Myc-Max and Mad-Max heterodimers 
determines cell decisions between proliferation/transformation 
and differentiation/quiescence (Eisenmann 1997). Indeed, 
increased expression of Mad proteins is associated with cellular 
differentiation and growth arrest. This occurs because Mad1-4 
proteins share a repression motif that interacts with Sin3a and 
Sin3b corepressors, which in turn recruit HDACs and other 
chromatin modifying proteins to the complex. In summary, the 
opposite functions of Myc and Mad may be explained at three 
levels: competition for available Max to form heterodimers; 
competition between heterodimers and E-box-binding sites; 
transcriptional activation and repression of bound genes (Cultraro 
et al., 1997; Farhana et al., 2015). Interestingly, Mnt is a unique 
antagonist of Myc among Max protein partners. Indeed, it is 
constitutively expressed, and its expression overlaps with the 
expression of Myc (Billin et al., 1999; Grandori et al., 2000; Link 
et al., 2012; Yang & Hurlin, 2017). Recent studies show that Myc 
and Mnt compete for binding to limiting amounts of Max and, in 
turn, Max availability is further modulated by the turnover of 
Mxd protein family, whch display a short half-life, by ubiquitin-
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mediated proteasomal degradation. Therefore, the complexity of 
the Myc-Max-Mad network implies a stoichiometric control of all 
its components. Moreover, Myc can also act as a transcriptional 
repressor at distinct subsets of genes impairing p300 recruitment 
by the transcriptional activator Miz-1 (Nair et al., 2006; Grandori 
et al., 2000). There are also differences in the subnuclear 
localization and binding affinities of Myc-Max and Mxd-Max 
complexes, indicating that the modulation of the levels of 
individual family members may have a distinct effect on network 
activity. Myc, for instance, is able also to upregulate the 
expression of MondoA and ChREBP, nutrient-sensing 
transcription factors, which control different facets of cellular 
metabolism, and their accumulation in the nucleus depends on 
changes in the metabolic flux. In turn, these two factors influence 
Myc-driven metabolic reprogramming during tumor progression 
(Lin et al., 2009; Kaadige et al., 2010). Furthermore, increased 
amount of MondoA and ChREBP sequestrates Mlx (Max 
dimerization protein X), increasing the competition between Myc 
and co-expressed Mxd proteins for Max. Therefore, an imbalance 
in the network may arise alterations typical of cancer cells.  
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Fig. 2 – The Myc/Max/Mad network. Schematic diagram of individual 
interactions among Myc network components (double-headed arrows), 
(Conacci-Sorell et al., 2014).  
 
1.3 Biological activities of Myc. In normal, non-dividing cells, 
Myc levels are low, while in dividing cells Myc expression is 
induced in a highly controlled manner and is maintained at a 
relatively constant, intermediate level during the cell cycle. This 
scenario changes when Myc expression overcomes two orders of 
magnitude in cancer cells. The control of Myc expression and 
activity starts at transcription. Myc is an intermediate early gene, 
rapidly induced in response to a wide range of growth factor, 
cytokines and mitogens, such as Wnt, Notch, Stat, receptor 
tyrosine kinases (RTKs), as well as hormone receptor pathways 
(Spencer and Groudine 1991; Morrow et al., 1992; Meyer et al., 
2008; Eilers and Eisenman 2008). Regulation of Myc 
transcription is exerted at both the initiation and RNA polymerase 
(RNAP) II pause release level upon proper mitogenic stimulation 
(Grandori et al., 2000). eIF4E binds the Myc message early 
during the transcription process, avoiding free Myc mRNA 
escape from the nucleus, without appropriate restraints. Once in 
the cytoplasm, translation of the Myc mRNA is finely regulated 
and temporally limited by its short half-life. The Myc protein is 
even subjected to several post-translational modifications 
including phosphorylation, acetylation, glycosylation, and 
ubiquitylation. The rapid Ub-mediated proteolysis of Myc is 
crucial for keeping Myc levels low (Vervoorts et al., 2003, 2006; 
Chou et al., 1995). Myc is required for maintaining pluripotency 
and self-renewal of embryonic, neural stem cells and progenitors 
(Knoepfler et al., 2002) and at the same time is also required for 
the exit from the stem cell niche, balancing differentiation and 
growth of progenitor cells (Wilson et al., 2004). Indeed, the 
suppression of myc expression is an essential component to 
trigger differentiation (Johansen et al., 2001) (Fig. 3). 
Interestingly, Myc and other transcription factors, such as Klf4, 
Oct4 and Sox2, are able to convert differentiated mouse and 
human fibroblasts into pluripotent stem cells (iPS) by affecting 
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the epigenetic state of the target cell (Takahashi et al., 2007; 
Laurenti et al., 2009; Singh and Dalton 2009). Another important 
Myc function is the ability to induce apoptosis. Specifically, 
normal cells seem to be sensitive to unchecked Myc expression 
and activate programmed cell death in this condition. This 
phenomenon depends on Myc expression levels and extracellular 
stimuli. In normal conditions, the presence of high concentration 
of growth factors, in response to sustained Myc levels, pushes the 
cells towards proliferation; in limited growth factors conditions, 
cells respond undergoing apoptosis. Conversely, transformed 
cells frequently resist the apoptotic effects induced by 
deregulated Myc expression, responding only to its pro-
proliferative signals (Zindy et al., 1998; Juin et al., 1999; Soucie 
et al., 2000; Eischen et al., 2001; Larsson and Henriksson 2010; 
McMahon 2014). To note, the ability of Myc to induce apoptosis 
in normal cells is consistent with the model in which Myc 
derepresses at least one level of apoptotic control, making cells 
more susceptible to death in only some contexts (Fig. 3). It is not 
clear whether Myc constitutively regulates all downstream 
effector pathways or whether each pathway becomes fully 
activated only upon the occurrence of a second stimulus. For 
example, both high levels of Myc expression and growth 
inhibitory signals are required to trigger cell death (Sears et al. 
1999). For this reasons, Myc-dependent apoptosis has been 
referred to as a Myc latent or intrinsic tumor suppressor activity. 
Further, Myc is able to induce cellular senescence, a mechanism 
which impairs tumor development at the pre-malignant stage, 
under certain conditions. In general low levels of Myc were 
shown to induce or inhibit senescence (Zhuang et al., 2008). This 
apparent contradiction suggests that the role of Myc in promoting 
senescence is strictly dependent from overlapping pathways, cell 
context and, more specifically, protective factors deficiency (Vita 
and Henriksson 2006; Campaner et al., 2010) (Fig. 3).  
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Fig. 3 – Myc biological activity. Depending on changes of the extracellular 
microenvironment Myc may affect several biological functions (Figure from 
Oster et al., 2001).  
 
1.4 Myc and cancer. Deregulation of the myc protoncogene is a 
catastrophic event which makes cells vulnerable to further 
oncogenic hits. In general, the principal hallmarks of cancer, 
acquired during the process of tumorigenesis, are self-sufficiency, 
growth signals, insensitivity to antigrowth signals, escape from 
apoptosis, sustained angiogenesis and tissue invasion with 
consequent metastasization. Myc may promote several of these 
capabilities simultaneously. Although myc gene alterations have 
initially been reported in a myeloid leukemia cell line (Dalla 
Favera et al., 1982b), they have also been found in colon 
carcinomas (Alitalo et al., 1983), in neuroblastoma, a childhood 
solid tumor with mycn gene amplification (N-Myc) (Khol et al., 
1983), in small cell lung carcinomas (l-Myc; Neu et al., 1985). 
After these initial findings, several studies had confirmed that 
genetic alterations of myc gene family member probably underlie 
the etiology of all cancers. Therefore, understanding how and 
when cells lose the control of Myc is crucial to predict tumor 
outcome and to design successful therapies. The principal 
alterations, such as viral insertional events, chromosomal 
 15 
 
translocations and gene amplification do not disrupt its protein 
sequence. Indeed, Myc deregulation in cancer does not depend on 
mutations in the coding sequence. High levels of Myc are due to 
the cell inability to modulate its expression in response to normal 
cellular and extracellular signals. Notably, aberrant Myc 
expression can be promoted by defects in signal-transduction 
pathways, which are frequently mutated in cancer, that activate or 
repress myc gene family expression, such as Wnt-β-catenin, Sonic 
hedgehog-Gli, and Notch (Vita and Henriksson 2006; Song et al., 
2015; Morris and Huang 2016). Myc activation occurs also at the 
post-transcriptional level by increasing both Myc mRNA (Vita 
and Henriksson 2006) and protein stability. In particular, it has 
been shown that the stability of the Myc mRNA is promoted by 
the overexpression of the eIF4E translation factor that exports 
Myc mRNA from the nucleus to the cytoplasm (Oster et al., 2002; 
Schmidt, 2004; Matsumoto et al., 2015) while the Myc protein is 
stabilized by loss of critical regulators, such as the SCFFbw7 
ubiquitin ligase (Yada et al., 2004; Popov et al., 2010). In this 
regard, it has been demonstrated that mutations of T58 or around 
this residue impair Myc ubiquitination and proteasome 
degradation in Burkitt’s lymphoma (Hoang et al., 1995; Chang et 
al., 2000; Cowling et al., 2014). Alternative mechanisms for the 
regulation of Myc stability involve the MBI and MBII conserved 
sequences, characterized by lysine residues which may be 
potentially ubiquitinated, while Myc PEST sequence has been 
shown to be necessary for its rapid turnover (Salghetti et al., 1999; 
Sears et al., 2000; Gregory and Hann 2000). When these Myc 
domains are mutated, the increased Myc stability contribute to 
tumorigenesis. Paradoxically, deregulation of Myc also triggers 
intrinsic tumor suppressor mechanisms including  apoptosis, 
cellular senescence, and DNA damage responses. These anti-
cancer mechanisms can be latent in tumor cells and can be 
activated or reactivated by molecular intervention (Lowe et al., 
2004).   
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2. Myc transcriptional activity 
 
The precise role of Myc in transcriptional regulation is still 
strongly debated. The predominant function of Myc-Max 
heterodimer is gene activation. This is consistent with Myc’s 
ability to recruit multiple coactivator complexes (Adhikary and 
Eilers 2005; Cole and Nikiforov 2006; Rahl et al., 2010, Poole 
and van Riggelen 2017). However, when the Myc-Max complex 
interacts with a zinc finger protein named Miz-1, Myc has been 
associated also with transcriptional repression (Wiese et al., 
2013).  Notably, as distinct types of cancer have different Myc 
expression levels (Fig. 4), the differential increase in Myc 
production may explain, at least in part, why different tumors 
acquire a specific Myc-dependent transcriptional profile (Tansey 
2014). Specifically, when Myc is at physiological levels, it 
weakly binds to low-affinity promoters, while high-affinity 
promoters may be already saturated. Therefore, Myc binds better 
to some promoters than others altering the activity of the 
corresponding gene (Zheng and Levens 2016; Lorenzin et al., 
2016; Allevato et al., 2017).  
 
A 
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Fig. 4 - The human protein atlas of Myc. A. RNA-seq data from The Cancer 
Genome Atlas (TCGA). B. The graph depicts Myc protein expression 
overview in different types of cancer. Protein expression level is shown for 
each cancer by color-coded bars. The y-axis indicates the percentage of 
patients. Cancer types are color-coded according to the organ of origin 
(https://www.proteinatlas.org/ENSG00000136997-MYC/pathology#top). 
 
Neverthless, the frequency of the E-boxes throughout the genome 
and the ability of Myc to bind also to sequences lacking these 
consensus regions makes difficult to predict specific sets of Myc-
regulated genes. Indeed, genome-wide approaches have revealed 
that Myc has a preference for certain chromatin states, which may 
not contain E-boxes. Generally, Myc binds to E-boxes located 
proximal to CpG islands, in chromatin regions carrying active 
histone marks, such as histone H3 methylation at lysine residues 
4 and 79 or H3 acetylation at lysine residue 27. Therefore, Myc 
transcriptional response may depend on the epigenetic state and 
on the type and history of each cell within a specific tumor (Eilers 
and Eisenman 2008; Zeller et al., 2006; Lin et al., 2012; Walz et 
al., 2014). Most of Myc-induced genes are transcribed by 
RNAPII. Some studies show that Myc additionally stimulates 
transcription of genes by RNAPIII (Gomez-Roman et al., 2003; 
Arabi et al., 2005; Grandori et al., 2005). Myc facilitates 
transcriptional elongation by stimulating the recruitment of P-
B 
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TEFb and Mediator complex and increases the levels of 
transcripts per cell. The Mediator complex is an essential co-
activator of RNAPII involved in chromatin “looping”, which 
brings distant chromosomal regions closer to each other. 
Specifically, MBI and MBII Myc box also mediate the 
association of Myc with Bromodomain Containing Protein 4 
(BRD4) that in turn promotes P-TEFb recruitment (Rahl et al., 
2010; Rahl et., 2014; Poole and van Riggelen 2017). It has to be 
considered that other factors prepare the chromatin to be easily 
recognized by Myc-Max (the so-called chromatin “open state”) 
and the interactions among chromatin-modifying proteins and the 
basal transcriptional machinery determine the localization of 
Myc-Max dimers at active loci. This is allowed by a sequence of 
a specific hierarchy of binding events. WDR5, BPTF, and TIP60, 
for example, are some of these helper factors that guide Myc to 
the promoters of active genes (Thomas et al., 2015; Kress et al., 
2015). Hence, the increase of Myc molecules amount, in tumors, 
may cause not only the saturation of high- and low-affinity 
binding promoters but also an abnormal increase of Myc co-
factors recruitment in protein complexes. This may contribute to 
altered transcription processes with consequent aberrant gene 
expression typical in cancer.  
2.1 Global versus selective: two conflicting models? Two 
models have been proposed for Myc function: Myc is a universal 
amplifier, which binds virtually to all active promoters in the 
genome, stimulating gene transcription, whereas the other model 
suggests Myc as a gene-specific regulator (specifier).  
Several studies support the idea that Myc is an amplifier because 
of its presence on promoters with an open chromatin structure, as 
well as on thousands of enhancers and intergenic sites in multiple 
cell types, globally enhancing transcription (Lin et al., 2012; Nie 
et al., 2012). As a consequence, Myc overexpression modulates 
the expression of genes involved in a broad range of biological 
functions, such as cell growth, ribosome biogenesis, protein 
synthesis, and metabolism (Eilers and Eisenman, 2008). In tumor 
cells, overexpressed Myc accumulates in the promoter regions of 
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active genes, causing transcriptional amplification in particular of 
proliferation-associated genes (Lin et al., 2012). Thus, while in 
normal cells Myc is induced by mitogenic growth factors (Dang 
et al., 2012; Eilers and Eisenman 2008; Meyer and Penn 2008), 
in tumor cells, its high expression uncouples growth-factor 
stimulation and cellular proliferation. Furthermore, elevated 
expression of Myc allows  global changes in chromatin 
architecture (Guccione et al., 2006; Knoepler et al., 2006; Van 
Riggelen et al., 2010), influencing transcription. Thus, Myc 
amplifies the output of existing gene expression programs by 
directly binding all actively transcribed genes at the E-box- 
containing core promoter sequences. Notably, the magnitude of 
Myc-driven transcriptional amplification depends on the levels of 
Myc within the cell. In tumor cells expressing low Myc, the 
transcription factor is bound almost exclusively to E-boxes of 
most actively transcribed genes. Conversely, elevated Myc binds 
also to the enhancers of these active genes and at low-affinity E-
box-like sequences, the so-called non-canonical E-boxes. In 
particular, differences in Myc occupancy determine the degree of 
expression of each active gene: high-affinity promoters are Myc-
saturated in proliferating cells and a further growth in Myc levels 
only increase its occupancy at low-affinity promoters (Walz et al., 
2014; Wolf et al., 2015) (Fig. 5).It has to be considered that the 
dose-dependent binding of Myc to chromatin may change even 
within a single cell population. This means that all Myc-bound 
sites in one cell may not necessarly correlate with those in another 
one (Tansey 2014). In summary, Myc is a universal amplifier 
because increased levels of Myc result in increased Myc binding 
to active genes. This behavior of Myc is consistent with the 
evidence that open chromatin at active promoters is important for 
Myc binding (Guccione et al., 2006) and that enhancer loops, in 
the proximity of core promoters at active genes, may facilitate 
binding of Myc to close enhancer elements, once Myc binding 
sites in core promoters are saturated. 
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Fig. 5 – Myc affinity at genome. The picture shows progressively increasing 
genomic Myc binding at (A) low, (B) medium and (C) high Myc 
concentrations (Wolf et al., 2015).  
 
To summarize, at high concentrations, Myc is not sequence-
independent, but it is simply less selective. 
This view of Myc transcriptional activity as an amplifier does not 
discriminate between direct and indirect Myc effects on gene 
expression. Myc activity modifies cell behavior in response to 
extracellular stimuli (either in normal or in pathological contexts), 
changing cell size, energy metabolism, translation, and nucleotide 
biosynthesis. These processes have a potential feedback on global 
RNA synthesis, processing, and turnover and are controlled by 
different Myc-regulated genes. Consistent with this evidence, 
RNA amplification is observed in different physiological 
transition states, such as quiescent versus activated, but also 
normal versus tumor or tumors with variable Myc levels (Fig. 6). 
Therefore, Myc may regulate specific gene sets that increase the 
expression of other indirect Myc target genes, through a sort of 
domino effect, rather than inducing a general amplification, and 
RNA amplification is independent from chromatin invasion 
(Perna et al., 2012; Sabò et al., 2014).  
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Fig. 6 – Schematic representation of Myc effects at different expression 
levels. Left: low Myc is required for selective regulation of a set of Myc-
dependent genes preceding S-phase entry and RNA amplification. Right: 
super-activation of Myc and chromatin invasion, but without further RNA 
amplification (Kress et al., 2015).  
 
In this view, global changes in RNA and mRNA levels occur 
indirectly as a consequence of Myc-driven cell growth (Sabò and 
Amati, 2014). This is in an apparent contradiction with the 
general amplification model, considering also that the specifier 
model proposes that most of Myc binding to chromatin is non-
productive in terms of transcriptional regulation (Kress et al., 
2015). New insights about Myc ability to widely affect gene 
expression come from the observation that the increasing amount 
of Myc, from normal to tumor-specific levels, do not affect Myc 
binding at promoters where the transcription factor is already 
strongly bound in normal cells. Indeed, Myc increases only at 
weakly bound promoters. In this view, the transition state from a 
normal to a tumor cell is due to abnormal Myc levels which locate 
at previously empty binding sites or with a lower Myc amount. 
Therefore, Myc regulates distinct sets of genes in normal and 
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tumor cells according to its concentration: it is a specifier in some 
biological settings; in others it enhances the expression of all 
genes as a general amplifier. This novel hypothesis overcomes 
the apparent contradiction between the specifier and the amplifier 
models (Lorenzin et al., 2016): a dose-dependent correlation 
exists between Myc concentration and gene response. Hence, 
Myc may contribute to oncogenic transformation via two 
different mechanisms: low levels of constitutive Myc enhance the 
expression of genes controlled by high-affinity promoters, such 
as genes involved in ribosome function. The further increase in 
Myc levels will enhance occupancy of promoters that are barely 
occupied in normal and proliferating cells, triggering 
tumorigenesis (Fig. 7).  
 
Fig. 7 – Schematic model of Myc DNA-binding ability. (A) high-affinity 
binding sites, e.g. E-boxes, are already highly occupied at physiological Myc 
levels (medium Myc), in dividing cells. At oncogenic concentration (high 
Myc) also low-affinity (low aff.) binding sites may become occupied by Myc 
and the up-regulation of these low-affinity genes is suggestive for 
transformation. (B) Different Myc levels regulate distinct biological processes 
(Lorenzin et al., 2016).  
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A very recent study provides important insight into Myc capacity 
to affect the gene expression as a specifier. Only few hundred of 
genes show decreased messenger RNA output upon Myc loss, 
while the large majority of the transcriptome remains unaffected 
(Muhar et al., 2018) (Fig. 8). This Myc-dependent signature is 
composed by a group of genes involved in protein and nucleic 
acid biosynthetic pathways, confirming that Myc mainly 
contributes to the activation of specific transcriptional patterns 
which, in turn, promote the increase in RNA biosynthesis, 
generally associated with cell activation and transformation 
(Kress et al., 2015).  
Based on these observations, the Myc expression levels are 
crucial to proper cellular function. Indeed, in normal cells Myc 
levels are finely regulated and Myc induces the expression of a 
specific set of genes (Sabò et al., 2014). In summary, during the 
transition from a quiescent to a proliferating state, Myc molecules 
(Fig. 6 and 7) increase, enhancing the expression of direct 
secondary target genes, that in turn promote the transcription of 
downstream genes (a domino effect). In tumors, at 
supraphysiological levels, Myc retains this ability but also 
overamplifies the transcription of genes which Myc normally 
does not or weakly binds (Lorenzin et al., 2016). This Myc 
behavior is called secondary RNA amplification (Fig. 8, late 
effects – indirect) in contrast to the genome-wide, direct 
transcriptional amplification model. In this view, the amplifier 
and the specifier model may be reconciled. 
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3. Omomyc 
About twenty-five years later the discovery of myc gene, Sergio 
Nasi and Laura Soucek engineered a small peptide of 90 amino 
acids, named Omomyc, able to interfere with Myc function 
(Soucek et al. 1998). Omomyc action is different when compared 
to drugs or RNA interference, designed to fully inhibit Myc 
activity. In several genetic mouse models of cancer, Omomyc 
exerts extraordinary therapeutic capacity, with mild and well-
tolerated side effects. Therefore, Omomyc is not only a tool to 
inhibit Myc activity to understand its molecular functions but 
represents also a hopeful and a successful agent for cancer 
therapy.  
 
3.1 Structure of Omomyc and its interactors. Omomyc is a 90 
amino acids Myc-bHLH mutant, with a molecular weight of 11 
KD. It was designed by the accurate analysis of the 
crystallographic structure of DNA-bound Max homodimers 
(Ferrè-D’Amarè et al., 1993), to identify those amino acids 
crucial for heterodimerization with Myc. Four are the amino acids 
located in the Myc leucine zipper involved in dimerization: two 
glutamate residues (E57, E64) and two arginines (R70, R71); the 
corresponding positions in Max are occupied by two asparagines 
(N57 and N71), one isoleucine (I64) and one glutamine (Q70). In 
Omomyc, Myc E57 is substituted by a threonine (T), while the 
other three amino acids are the same as in Max (Fig.10). Omomyc 
also lacks Myc transactivation domain, it efficiently 
homodimerizes, can still heterodimerize with Myc, Max and Miz-
1 (Soucek et al. 1998; Savino et al., 2011; Jung et al., 2017). 
Omomyc forms a complex with Max with high efficiency, like 
Myc/Max dimers, while DNA binding affinity of Myc-Omomyc 
heterodimer is low (Soucek et al., 1998).  
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Fig. 10 – bHLH sequence comparison of Max, Myc and Omomyc. 
Amino-acidic bHLH sequence are shown. Red rectangles highlight the four 
mutated amino-acids. 
In the presence of Omomyc, Myc-dependent gene transcription 
undergoes general repression. This occurs because Omomyc 
selectively targets Myc protein interactions, as confirmed by its 
binding with Miz-1, a known Myc co-repressor (Wiess et al., 
2013). Specifically, Omomyc interferes with Myc binding to E-
boxes and prevents the transactivation of target genes, retaining 
Myc transrepression properties in association with Miz-1. In 
parallel, broad epigenetic changes occur, such as decreased 
acetylation and increased methylation at lysine 9 of histone H3 
(Savino et al., 2011). Further, both Myc and Omomyc 
functionally associate with the Methylosome 50-Protein Arginine 
Methyltransferase 5 (PRMT5-MEP50) complex, inducing H4R3 
symmetric di-methylation (H4R3me2s), supporting Omomyc 
function as a transcriptional repressor of Myc target genes 
(Mongiardi et al., 2015). Consistently, Omomyc induces histone 
deacetylation while Myc promotes acetylation (Savino et al., 
2011, Ullius et al., 2014; Mongiardi et al., 2015). These findings 
further suggest that Omomyc may be considered a sort of 
transcriptional repressor. A recent and accurate crystallographic 
analysis (Fig.11) confirms that Omomyc forms more stable 
homodimers compared to Myc-Max heterodimers because of 
ionic and hydrophobic interactions. Indeed, Omomyc dimers with 
Myc or Max appear to contain repulsive interactions or to lack 
stabilizing interactions that decrease their stability, suggesting 
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that Omomyc preferentially forms homodimers (Savino et al., 
2011; Jung et al., 2017). Omomyc homodimers bind DNA with 
higher affinity compared to Myc-Max complexes, showing also a 
competition for E-boxes binding (Jung et al., 2017).  
Fig.11 – Structure and DNA binding of Omomyc. Crystal structure of the 
Omomyc homodimer bound to a consensus E-box. The CACGTC sequence is 
highlighted in blue (Jung et al., 2017). Omomyc forms a homodimer with an 
overall structure that is very similar to those other b/HLH/Zip structure, in 
particular to that of Myc-Max.  
 
3.2 Overview of Omomyc action in cancer. The outstanding 
capacity of Omomyc to inhibit Myc oncogenic action is supported 
by several in vitro and in vivo studies. Omomyc can potentiate 
Myc-induced apoptosis and, inhibiting Myc DNA-binding to the 
E-boxes, antagonizes Myc-induced papillomatosis (Soucek et al., 
2002). While Myc-induced apoptosis requires ARF and p53, 
Omomyc-dependent apoptosis does not require ARF, although 
p53 remains necessary. Its proapoptotic action is most likely 
related to Myc transrepression function and it is intriguingly 
limited only to cells harboring activated Myc (Soucek et al., 2004; 
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2010). Surprisingly, Omomyc prevents the development of lung 
tumors and trigger their rapid regression, with well-tolerated and 
reversible systemic side effects, upon restoration of Myc function 
(Soucek et al., 2008, 2013). Moreover, Omomyc suppresses cell 
growth by inducing apoptosis or cell cycle arrest in G1, targeting 
Myc in several types of Myc-addicted lung tumor cells 
(Fiorentino et al., 2016). The ability of Omomyc to be a potent 
tumor-suppressor, is further demonstrated by studies on glioma in 
vitro and in vivo. Here, the small peptide suppresses glioma 
formation, inhibits glioma cell proliferation and survival, and 
triggers regression of established disease in mice (Annibali et al., 
2014). Additionally, Omomyc induces differentiation in specific 
stimuli conditions (Grayson et al., 2014). The little toxicity in  
Omomyc expressing normal tissues may be due to the capacity of 
Omomyc in discriminating between physiological and oncogenic 
functions of Myc (Fig. 12). Indeed, Omomyc causes a significant 
decrease in Myc promoter occupancy preferentially at binding 
sites invaded by oncogenic Myc levels, attenuating both Myc-
dependent activation and repression of the gene expression (Jung 
et al. 2017).  
 
Fig. 12 – Omomyc occupancy increases at low affinity promoters that are 
invaded by oncogenic Myc levels (Jung et al. 2017).  
 
 
 28 
 
4. Experimental models 
 
4.1 Glioblastoma multiforme (GBM). Glioblastoma multiforme 
is one of the most malignant tumors of the brain, that remains 
largely incurable and with a poor prognosis. Patients usually have 
a median survival of 14 to 18 months from the diagnosis. With a 
global incidence of 10 per 100,000 people, it can occur at any age, 
but the peak is between 55 to 60 years (Jansen et al., 2010; Hanif 
et al., 2017). Glioblastoma stem cells (GSCs) are responsible for 
GBM development, progression, maintenance and tumor 
recurrence. They are multipotent, resistant to therapies and they 
are located in specific niches, characterized by different stromal 
cells such as mesenchymal and immune cells, with abnormal 
extracellular matrix components and an atypical vascular 
network. Furthermore, they are characterized by developmental 
and repair programs, typical of normal stem and progenitor cells, 
to support the expansion of the tumor (Lee et al., 2006; Bao et al., 
2006; Cloughesy et al., 2014; Lathia et al., 2015) (Fig. 13). 
Glioma stem cells express high Myc levels (Wang et al., 2008), 
which are required to sustain GSCs phenotypic features such as 
growth, proliferation, self-renewal and survival. Indeed, it 
correlates with the grade of malignancy (Herms et al., 1999). 
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Fig. 13 - Schematic representation of the cancer stem cell in glioma. Current 
therapies target highly proliferating cells, leaving a small population of 
quiescent cells that are thought to be responsible for tumor recurrence 
(Seymour et al., 2015).  
4.2 Burkitt’s lymphoma (BL). Burkitt’s lymphoma is the fastest 
growing human tumor and is a highly aggressive B-cells, non-
Hodgkin lymphoma. Infection by the Epstein Barr Virus (EBV) 
precedes tumorigenesis. The incidence is frequent in childhood 
and increases in immuno-depressed patients such as in HIV 
infection (Molyneux et al., 2012). Burkitt’s lymphoma is 
characterized by a significant deregulation of myc gene. Here, 
myc is involved in reciprocal Burkitt translocations [t (8;14), t 
(8;22), and t (2;8)] (Fig. 14). In t (8;14) human Burkitt cell lines, 
myc is directly translocated into the heavy chain locus of 
immunoglobulin (IGH) (Dalla Favera et al., 1982; Taub et al., 
1982; Molyneux et al., 2012) and it is under the control of the 
IGH promoter, a phenomenon crucial for tumorigenesis. 
However, Burkitt’s lymphoma cases without myc gene 
rearrangement but with high Myc expression levels and DNA 
methyltransferases (DNMT family member) deregulation have 
been identified (De Falco et al., 2015). Furthermore, in a certain 
number of Burkitt’s lymphoma cell lines, Myc protein is also 
significantly stabilized, suggesting that aberrant Myc proteolysis 
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may play a crucial role in the pathogenesis of Burkitt’s lymphoma 
(Mark et al., 2000).  
 
 
 
 
 
 
 
 
 
Fig. 14 – Burkitt’s lymphoma mutation. The figure depicts a typical 
reciprocal chromosome translocation t (8;14), involving myc gene in BL.  
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AIM OF THE RESEARCH 
Deregulation of Myc, common in several human cancer, makes 
the Myc protein an attractive therapeutic target. Omomyc is a 
mutant of Myc at the bHLH domain that affects Myc function at 
the level of protein interactions and DNA binding and strongly 
reduces Myc tumorigenic properties in vitro (Soucek et al., 1998; 
Savino et al., 2011). Omomyc displayed therapeutic efficacy in a 
variety of mouse transgenic models, such as Myc-induced 
papillomatosis, lung carcinoma, pancreatic islet tumor, glioma 
and others, with very well tolerated side effects in vivo (Soucek 
et al., 2002; Annibali et al., 2014). Thus, it is important to 
elucidate how Omomyc works at the cellular and mechanistic 
level in tumor cells besides its use as a tool to dissect the Myc 
molecular function in cancer. Glioblastoma multiforme (GBM) 
and Burkitt’s lymphoma (BL) are two very aggressive tumors in 
which Myc contribute to maintain oncogenic programs (De 
Bacco et al., 2014; Dalla Favera et al., 1982; Cesarman et al., 
1987). The aim of this research was to interfere with Myc action 
using Omomyc in Brain Tumor 168 (BT168) and Ramos cells, 
derived respectively from human GBM and BL specimens. 
Specifically, our first interest was to evaluate the impact of 
Omomyc expression at the transcriptional level to identify the 
genes most significantly and differentially modulated by Myc 
inhibition in BT168 cells. This may lead to a better understanding 
of the gene networks critical for the GBM phenotype and pivotal 
to the anti-tumorigenic properties of Omomyc. In the second part 
of the project, considering that Myc regulates many aspects of 
transcription, from initiation to elongation and that Myc and 
PRMT5 functionally interact (Rahl et al., 2010; Mongiardi et al., 
2014), we investigated a potential role of Myc in the PRMT5-
dependent symmetrical di-methylation of R1810 residue at the 
carbossi-terminal domain (CTD) of RNA polymerase II 
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(RNAPII), required for termination process and splicing of the 
transcripts (Zhao et al., 2016).   
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5. Results 
5.1 Omomyc suppresses tumorigenic features of glioblastoma 
stem-like cells and Burkitt’s lymphoma cells. Omomyc is a 
potent tumor suppressor able to induce apoptosis and inhibit 
oncogenesis (Soucek et al., 2002 and 2008; Annibali et al., 2014). 
To better investigate the impact of Myc inhibition we employed 
the doxycycline-inducible pSLIK-Flag-Omomyc (FO) lentivirus 
(Fig. 1 A). We stably transduced the lentivirus in BT168 GSCs 
(De Bacco et al. 2012) and BL cells Ramos (Dalla Favera et al., 
1982). Omomyc was detectable at 4–12 h post-doxycycline 
(DOX) treatment, reaching maximal levels at 36h-48 h (Fig. 1 B).  
 
 
 
Fig. 1 - (A) Scheme of the inducible lentiviral expression vector pSLIK-Flag-
Omomyc. I. In the absence of DOX, transactivator protein is not bound to the 
TRE (Tetracycline Responsive Element) promoter and Flag-Omomyc is not 
A 
B 
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expressed. II. DOX treatment induces conformational changes of 
transactivator protein which binds to TRE and promotes the Flag-Omomyc 
expression. (B) Representative immunoblots of Flag-Omomyc and -Actin or 
Tubulin loading controls upon DOX treatment in BT168FO cells for 0–48h 
and Ramos FO cells for 0-36h. 
 
DOX treatment caused a reduction of proliferation in BT168FO 
cells but not in control cells expressing a DOX-inducible green 
fluorescent protein (BT168GFP) (Fig. 2 A). Further, Omomyc 
expression induced a strong decrease of GSCs self-renewal 
capacity and neurosphere size (Fig. 2 B). In support to this 
observation, Omomyc decreased also the expression of genes 
involved in neural stem cell self-renewal and proliferation, such 
as SOX2, NOTCH1, CCND1 (cyclin D1), MYC and NESTIN 
(Gangemi et al., 2009; Piccin et al., 2013; Matsuda et al., 2015), 
while PTEN, a tumor suppressor, able to enhance differentiation 
and inhibit cell renewal (Zheng et al., 2008), increased (Fig. 2 C). 
Also, the migratory ability of GSCs, which accounts for their 
capacity to infiltrate the tumor (Chen et al., 2014), was strongly 
restrained by Omomyc (Fig. 2 D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B  A 
D C 
Galardi et al., 2016 
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Fig. 2 - Omomyc inhibits GSC cell proliferation, self-renewal, and 
migration. (A) Proliferation curves of BT168FO and BT168GFP cells upon 
DOX treatment for 0–96h (n=3; mean ± SD). Viable cells were counted using 
a hemocytometer. (B) Self-renewal assay upon DOX treatment. Left. 
Histograms show the percentage of BT168FO cells capable of re-forming 
neurospheres 7 days after dissociation and treatment (n=3; mean ± SD). Right. 
Representative image of neurospheres. (C) Evaluation, by qRT–PCR, of GSC 
markers’ mRNA, CCND1, MYC, SOX2, NOTCH1, NESTIN and 
differentiation markers PTEN in BT168FO cells after 48h of DOX treatment, 
compared to uninduced cells (n=3; mean ± SD). (D) Transwell migration assay 
of BT168FO cells after 3 days with or without DOX treatment (n = 3; mean ± 
SD). Ten fields per assay were counted. 
In RamosFO cells, Omomyc expression strongly reduced G1 
phase progression (Fig. 3 A), increased the apoptotic rate (Fig. 3 
B) (Soucek et al., 2002; Fiorentino et al., 2016), and upregulated 
the expression of the cell cycle inhibitor p21 (Fig. 3 C). This 
suggests that the cell cycle inhibition and apoptosis induction by 
Omomyc in Ramos cells may be related to an increase in p21 
protein expression (Abbas et al., 2009).  
 
 
 
 
Fig. 3 - Omomyc inhibits cell cycle progression and increases apoptosis 
rate in RamosFO cells. (A) Cell cycle analysis following 12-36h DOX 
treatment. Cells were analyzed for cell cycle distribution by PI staining and 
flow cytometry. Histograms show the percentage of cells distributed 
respectively in G1, S and G2 phases (n=3, mean ± SD. Statistical analysis was 
performed by one-way ANOVA, p-value ≤ 0,05). (B) Apoptotic cell death 
analysis after 12-36h DOX treatment. Apoptosis was determined using the 
B 
A
C
V
V 
C 
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Annexin V-FITC/PI double marked method by flow cytometry (n=2, mean 
±SD). (C) Representative immunoblot showing p21 and β-actin loading 
control upon 48h DOX treatment of Ramos FO. 
5.2  Impact of Omomyc expression on Myc genome 
occupancy. Myc binds to E-boxes of thousands of genomic loci 
with Max (Conacci-Sorrell et al., 2014), Omomyc inhibits 
Myc/Max heterodimers formation (Soucek et al., 1998). To 
assess the impact of Omomyc expression on Myc DNA binding, 
we performed chromatin immunoprecipitations with antibodies 
against Myc and Flag, followed by DNA sequencing (ChIP-seqs) 
in BT168FO cells treated or not with DOX for 24h. In untreated 
cells, we detected over 12,000 Myc peaks: 36% were localized at 
promoters, corresponding to 21% of all RefSeq promoters 
defined as -1,000 to + 100 bp regions surrounding the 
transcription start site (TSS), 37% were intragenic and 27% 
intergenic (Galardi et al., 2016). Omomyc expression led to a 
strong and genome-wide attenuation of Myc signals at promoters 
(Fig. 4). This was paralleled by the appearance of Omomyc 
signals in the same regions, as shown by the heat maps (Fig. 4 – 
left) and signal profiles of gene clusters (Fig. 4 – right). Further, 
in BT168FO cells, Omomyc distribution at the genomic loci of 
each gene clusters of Fig. 4 seems to overlap with Myc occupancy 
in uninduced cells. Indeed, Omomyc binds sequence motifs also 
bound by Myc in the minus DOX condition, as indicated by the 
motif enrichment analysis (Table 1, Galardi et al., 2016). 
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Fig. 4 – Genome wide attenuation of Myc binding around TSSs upon 
Omomyc expression. Left. Seq-miner heatmaps of Myc and Omomyc 
occupancy at TSS of all Myc promoter-target genes in BT168FO, in the 
presence or absence DOX for 24h. TSSs regions are ranked by decreasing Myc 
occupancy in untreated cells. Colour scaled intensities are in units of tags per 
50bp. The plots on the right depict Myc and Omomyc binding at cluster genes 
indicated by arrows, in cells, in the presence or absence DOX. 
 
 
 
 
 
 
 
 
Galardi et al., 2016 
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Table 1  
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Patterns of Myc and Omomyc ChIP-seq signals on three known 
Myc target genes - NCL (nucleolin), ODC (Ornithine 
decarboxylase) and MIR17HG (miR-17-92 microRNA cluster 
host gene) were thoroughly analyzed. Omomyc was enriched at 
target promoter regions upon the decrease of Myc signals, except 
for MIR17HG (Fig. 5 A).  
We observed that Omomyc caused a significant increase in Max 
protein expression in parallel with a decrease of Myc protein 
expression in both DOX induced BT168FO and Ramos FO cells 
(Fig. 5 B). Therefore, we asked whether Omomyc replaces Myc 
on the genome in partnership with Max. For this purpose, we 
performed qChIP assays with Max antibody. Surprisingly, we 
found that Max binding was strongly impaired in the presence of 
Omomyc suggesting that Omomyc does not bind to DNA in a 
complex with Max (Fig. 5 C). Omomyc likely binds chromatin 
as homodimers, which is the most abundant form within cells 
(Savino et al., 2011; Jung et al., 2017).  
 
 
 
 
 
 
 
 
A
C
V
V 
Galardi et al., 2016 
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Fig. 5 - Omomyc attenuates Myc and Max binding at DNA. (A) Myc (blue) 
and Flag-Omomyc (red) ChIP-seq signals at Myc target genes in treated and 
untreated BT168FO cells: NCL, MIR17HG and ODC. (B) Representative 
immunoblots of BT168FO and Ramos FO cells induced for 24h and relative 
quantification of Myc and Max proteins expression, p-value** 0,01; p-
value*** 0,0009 (mean ± SEM. Statistical analysis was performed by paired 
t-test). (C) qChIP assays from BT168FO cells, in the presence or absence 
DOX, and immunoprecipitated by Flag, Myc and Max antibodies (Galardi et 
al., 2016). 
 
B 
C 
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To investigate the global impact of Omomyc on the transcriptome 
and to analyze its relationship with Myc binding, we performed 
RNA-seq and compared the results with ChIP-seq. We defined 
the significantly modulated transcripts through CuffDiff2, as well 
as by applying a fold change cut-off (log2FC ≥ 0.25 or ≤ −0.25) 
and a P‐value threshold. We also assessed significantly 
modulated Myc targets by Gene Set Enrichment Analysis 
(GSEA, www.broadinstitute.org/gsea/). The outcomes of these 
approaches were coherent (Galardi et al., 2016).  
The analysis showed that 94% of Myc promoter-targets were 
transcribed (FPKM>0; FPKM: Fragments Per Kilobase of gene 
Million mapped reads). Myc promoter occupancy, defined in 
methods, grew together with transcript levels, confirming the 
correlation between increased transcription and increased Myc 
binding (Lin et al., 2012; Wolf et al., 2015). Myc promoter 
occupancy in the presence of Omomyc was reduced by 40-50% 
(Fig. 6 A, B) and the expression of Myc target genes was no 
longer Myc-dependent. Further, we found that Myc occupancy of 
downregulated genes (log2FC ≤ −0.25) was increased by 18% 
compared to upregulated genes (log2FC ≥ 0.25) in uninduced cells 
(Fig. 6 C). Although Myc occupancy was halved in both groups 
of genes in the presence of Omomyc, the difference in Myc 
occupancy between downregulated and upregulated genes was 
maintained, but in opposite manner: upregulated genes showed 
10% increase of Myc occupancy compared to downregulated 
genes (Fig. 6 C).  
 
 
 42 
 
 
 
 
 
 
 
 
Fig. 6 - Myc and Omomyc occupancy on the genome. (A) Myc and Omomyc 
promoter occupancy correlate with transcript levels. Binned scatter plot 
displays Myc and Omomyc ChIP-seq reads at promoters (-1,000, +100 regions 
with respect to TSS) versus transcript levels (FPKM from RNA-seq data) in 
BT168FO cells untreated or upon 24h of DOX. (B) Scatter plot depicting the 
correlation between Myc occupancy in untreated versus treated BT168FO 
cells. (C) Bar graph shows the average of Myc occupancy, in the absence or 
presence of DOX, of Myc promoter-targets both downregulated and 
upregulated by Omomyc in BT168FO cells (cut off absolute value log2 FC 
0,25). 
 
 
 
 
 
A B 
C 
y=0,40x+0,20 
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5.3 Impact of Omomyc on GSCs transcriptome. Albeit we 
found that in untreated cells 94% of Myc promoter-targets were 
transcribed (Galardi et al., 2016), Omomyc expression does not 
modulate the gene expression of the majority of Myc targets, that 
we classified as unchanged (Fig. 7 A). Nevertheless, by 
comparing the average value of the expression level of Omomyc 
downregulated and upregulated Myc target genes in untreated vs 
treated BT168FO cells, we observed that, in the absence of 
Omomyc, downregulated genes were more highly expressed than 
the upregulated. This difference was maintained upon Omomyc 
expression (Fig. 7 A, B). Moreover, the degree of Omomyc 
influence on gene expression is described by a strong linear 
correlation between the expression level of genes at 0h versus 24h 
of Omomyc induction (Fig. 7 C). Indeed, we observed that as the 
expression of genes increases, the probability that these genes 
will be repressed by Omomyc increases (Fig. 7 D); conversely, 
Myc target genes expressed at a lower level in the absence of 
Omomyc are both 20% upregulated or downregulated (Fig. 7 E). 
Extending the analysis to all the genes, we found that Omomyc 
affected also the expression of those not directly bound by Myc, 
albeit most of the them were unchanged (Fig. 8 A). Nevertheless, 
also, in this case, the most highly expressed genes were 
preferentially downregulated by Omomyc (Fig. 8 B).  
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A B 
Downregulated 87,60 68,37 12% 159
Unchanged 76,55 73,36 74% 1008
Upregulated 17,57 22,46 15% 204
Myc promoter-targets 
(average FPKM)
n°genes
All Myc promoter-targets 
C 
   All Myc promoter-targets 
(24h) (24h) 
-DOX +DOX 
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Myc promoter-targets (1≤FPKM≤100 in -DOX) 
y=0.8x-0.22 
y=1.25x+0.43 
D Myc promoter-targets (FPKM≥100 in -DOX) 
E 
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Fig. 7- Omomyc effect on the expression of Myc promoter-targets. (A) The 
table shows the average of FPKM of Myc targets (FPKM≥1) subdivided in 
downregulated, upregulated and unchanged genes upon 24h of Omomyc 
induction in BT168FO cells. (B) Box plot depicts the FPKM average values of 
downregulated or upregulated Myc targets in the presence or absence of 
Omomyc. n=3. The horizontal lines indicate median, whiskers extend to 1.5x 
interquartile range, while outliers are not shown. P-values (p) were calculated 
using two-sided, paired Wilcoxon signed-rank test. (C) Transcript level 
distribution (cut off absolute value log2 FC 0,25) of all Myc targets 
significantly downregulated (red dots) or up regulated (green dots) in cells 
treated with Dox for 24h versus untreated cells. Transcript levels, expressed as 
FPKM, represent the mean of three independent experiments. (D-E) Transcript 
level distribution of highly expressed Myc targets (FPKM≥100) or moderately 
expressed (1≤FPKM≤100). 
 
 
Downregulated 39,52 29,27 9% 833
Unchanged 41,61 42,06 69% 6221
Upregulated 12,33 16,02 22% 2013
n°genes
All the rest of genes 
(average FPKM)
A 
B 
y=1.26x+0.42 
y=0,80x-1.7 
-DOX +DOX 
non-Myc targets  
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Fig. 8 – Impact of Myc inhibition on non-Myc targets.  (A) The table shows 
the mean FPKM of non-Myc targets (FPKM>1) subdivided in downregulated, 
upregulated and unchanged genes upon 24h of Omomyc expression in 
BT168FO. (B) Dispersion graph shows the strong correlation (R=0,98 and 
R=0,99) between transcript level distribution of genes (cut off absolute value 
log2 FC 0,25) significantly downregulated (red dots) or upregulated (green 
dots) in cells treated with DOX for 24h versus untreated cells (0h). Transcript 
levels, expressed as FPKM, represent the mean of three independent 
experiments.  
 
To clarify the function of Omomyc modulated genes, we 
investigated the overlap of genes regulated by Omomyc at 4, 8, 
16, 24 and 48 h in BT168FO cells with the hallmark gene sets of 
the Molecular Signature Database (MsigDB). For Myc targets, 
we found highly significant overlaps with gene sets related to 
epithelial-mesenchymal transition, TNFA signaling via NF-κB, 
hypoxia, angiogenesis, inflammatory response, p53 signaling, 
glycolysis, WNT beta-catenin signaling, mitotic spindle, UV 
response, E2F targets at 4h – 8h of Omomyc induction. At 16h - 
48h, instead, we observed a significant modulation of MTORC1 
signaling, DNA repair, KRAS signaling, NOTCH signaling, 
G2M checkpoint, oxidative phosphorylation (Fig. 9 A). Hence, 
we observed an early and delayed specific action of Omomyc in 
modulating pathways in which Myc may have a role (Fig. 9 A). 
The same analysis was performed on non-Myc targets and 
showed a significant modulation of pathways overlapping those 
associated to Myc targets, such as hypoxia, oxidative 
phosphorylation, G2M checkpoint, DNA repair, UV response 
(Fig. 9 B). The appearance of different pathways in MsigDB 
analysis at early and longer times of Omomyc induction was 
coherent with the growing number of genes – both Myc and non- 
targets - modulated by Omomyc throughout the time course (Fig. 
9 C). This suggests that Omomyc may affect the expression of 
specific gene sets, that, in turn, cause a sort of domino effect, 
resetting the transcription of key gene networks for GSC 
phenotype.  
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Fig. 9 - Gene Set Enrichment Analysis (GSEA) - MSigDB of all genes 
significantly modulated by Omomyc in BT168FO cells. (A) Enrichment of 
MsigDB hallmark gene sets among genes with a Myc peak, at promoter, 
intragenic, and intergenic regions in BT168FO cells and whose mRNAs are 
modulated by Omomyc (estimated by CuffDiff2 and GSEA; q-value ≤0,05). 
(B) Enrichment of MsigDB hallmark gene sets among all non-Myc target 
genes significantly modulated by Omomyc (estimated by CuffDiff2 and 
GSEA; q-value ≤ 0,05). FDR q-values were computed through GSEA (FDR 
q-values ≤ 0,05). Bar colours indicate the different time points of DOX 
treatment (0-48h), while their height represents the log0,05 of the FDR q-value 
of each gene set. (C) Each bar shows the increasing number of genes 
significantly (q-value ≤0,05) modulated by Omomyc along the time course 0-
48h of DOX treatment.  
These data show that Omomyc inhibits Myc activity at DNA-
binding level and affects the expression of Myc-dependent gene 
regulatory networks.  
 
5.4 Omomyc minimally – or not at all - influences the global 
RNAPII binding at promoters and affects transcription in a 
subset of target genes only. Myc is found at promoters of all 
active genes, triggering transcriptional amplification by pausing 
release, with consequent increase of transcripts level (Rahl et al., 
C 
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2010; Lin et al 2012; Nie et al., 2012). We asked whether Myc 
replacement by Omomyc would influence RNA polymerase II 
(RNAPII) loading at promoters and transcriptional elongation. To 
this aim, we performed ChIP-seq experiments in BT168FO cells 
using a RNAPII antibody in the presence or absence of Omomyc 
and compared the results with RNA-seq. We did not observe 
relevant global changes of RNAPII loading around TSSs (Fig. 10 
A). Further, we analyzed RNAPII traveling ratio (TR), an index 
for evaluating the pause release (Rhal et al. 2010), from the 
RNAPII ChIP-seq experiments in minus versus plus Dox. We 
found that Omomyc minimally changes the TR, suggesting that it 
does not significantly impact on pause release (Fig. 10 B). These 
data suggest that Omomyc only marginally affects RNAPII 
loading at promoters and pause release.  
However, we asked whether loss of Myc binding, Omomyc 
presence at Myc genomic loci and RNAPII distribution were 
correlated to a specific set of genes. To this aim, we analyzed 
OLIG2 and miR-17-92, together with NCL, HDAC1 and 
DUSP10. They all were expressed at good levels (FPKM> 4) in 
BT168FO cells and showed a decrease of Myc binding at their 
respective promoters (blue; Fig. 10 C) upon Omomyc induction. 
Indeed, NCL, miR-17-92 and OLIG2 clearly displayed decreased 
transcript levels (Fig. 10 D). Omomyc binding (green; Fig. 10 C) 
was associated with minimal changes of RNAPII signals at TSSs, 
except for OLIG2. No correlation was observed between 
decreased Myc binding and transcript levels of HDAC1 and 
DUSP10, whose mRNA levels were barely affected by Omomyc 
(Fig. 10 C and D). To note, a reduction of RNAPII signals at 
transcription termination sites (TTSs) was found for OLIG2 and 
miR-17-92 (Fig. 10 C). NCL and miR-17-92 are well-known Myc 
upregulated targets in different cell contexts; on the contrary, 
Myc-dependent regulation of OLIG2, one of the master 
controllers of neural stem cell behavior, was unknown.  
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Fig. 10 – Correlation between RNAPII, Myc and Omomyc occupancy. (A) 
Heatmap of RNAPII signals around TSSs of Myc promoter-target genes in 
BT168FO cells, in the presence or absence of DOX for 24h. The data are 
ranked by decreasing Myc occupancy in uninduced BT168FO cells. Each row 
shows the ± 5 kb region centred on TSSs. Colour scaled intensities are in 
tags/50 bp. (B) Traveling ratio of RNAPII from ChIP-seqs in the presence or 
absence of Omomyc. (C) RNAPII tracking by ChIP-seq at NCL, OLIG2, miR-
17-92, HDAC1 and DUSP10 genes in BT168FO cells (-/+DOX). The y-axis 
displays RNAPII binding signals as tags/500 bp per million reads, whereas x-
axis shows genomic positions. Arrowheads indicate the direction of 
transcription. In blue Myc peaks and in green Omomyc peaks, grey boxes are 
TSS regions. (D) Gene expression levels of genes shown in B (n=3).  
 
5.5 Myc strengthens the regulatory nodes of glioblastoma 
gene expression networks. The direct regulatory functions of 
Myc remain debated. Two models have been proposed to explain 
its function: one proposes that Myc acts as a universal amplifier 
of all active genes (Lin et al., 2012; Nie et al., 2012), while the 
other model defines Myc as a specifier, that is a gene-specific 
regulator (Walz et al., 2014; Sabò et al., 2014). Altogether, our 
previous observations do not clarify whether Omomyc affects 
GSCs transcriptome directly or indirectly and how the changes of 
the expression of many genes may have a tumor suppression-
specific effect. A possible explanation may be that Omomyc 
affects the control points of gene expression networks that sustain 
cancer stem cell behavior.  
To test this hypothesis, we investigated the expression level of a 
set of genes selected for being related to such control points, 
according to literature data. We considered some universal Myc 
targets, by which Myc exerts its tumorigenic properties, 
transcription factors and other effectors involved in tumorigenesis 
and tumor suppression in several tumors, including GBM, and 
cell-specific factors that maintain GSCs phenotype (Suvà et al., 
2014). We analyzed Myc targets CCND1, CDK6 and NCL and 
the miR-17-92 cluster, which have a role in cell proliferation, cell 
growth control and glioblastomagenesis (Daniel et al., 2014; 
Bellail et al., 2014; Goldsmith et al., 2014). Moreover, miR-17-
92 inhibits, in turn, the expression of chromatin regulatory genes 
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like Sin3b (cellular senescence regulator), Hbp1 (neurogenesis 
regulator) and Btg1 (neuronal precursor regulator), maintaining a 
neoplastic state (Li et al., 2014). They were all strongly 
downregulated by Omomyc (Fig. 11 A). Furthermore, Omomyc 
expression repressed FOS, JUN and ID4 transcripts, encoding 
transcription factors that have a role in GBM onset and 
progression. On the contrary, Omomyc upregulated the tumor-
suppressive phosphatases PTEN and PPP2R5A (protein 
phosphatase A regulatory subunit), a regulator of mitotic 
progression, and the long non-coding RNA (lncRNA) 
MIAT/GOMAFU, involved in neurogenic commitment and 
differentiation (Aprea et al., 2013). We also examined the dual 
specificity protein kinase phosphatases (DUSPs) which control 
MAP kinase signaling. Omomyc can affect components of this 
family genes in either direction. Notably, Omomyc strongly 
affected the expression of DUSP 4, 5, 6 (Fig. 11 A) which have 
been implicated in glioblastomagenesis (Prabhakar et al., 2014).   
GSCs phenotype in vitro and in vivo is maintained by a set of 19 
TFs. A core subset of four of these TFs are enough for 
maintaining of GSC phenotypes. The four core TFs target a set of 
325 genes (Suvà et al., 2014). By GSEA, we found that the set of 
19 GSC-specific TFs was significantly associated with repression 
in response to Omomyc (Fig. 11 A). Omomyc downregulated the 
expression of three of the four core TFs, specifically POU3F2, 
OLIG2, and SOX2. Also, KDM1A (LSD1) lysine-specific 
histone demethylase/RCOR2 complex, which is a key effector of 
OLIG2 in GSCs, is repressed by Omomyc (Suvà et al., 2014; 
Yang et al., 2011). All these genes are Myc targets and their 
respective target genes were repressed by Omomyc (Fig. 11 A). 
Interestingly, Myc-dependent signatures, typical of other cell 
types, were significantly modulated by Omomyc in GSCs (from 
MSigDB Database v6.2). By GSEA-MSigDB software, we found 
that several Myc-upregulated gene signatures were 
downregulated by Omomyc in GSCs, while the opposite 
happened for Myc-downregulated gene signatures (Fig. 11 B and 
C). In conclusion, Myc inhibition by Omomyc not only strongly 
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influenced the transcript levels of key TFs responsible of GSC 
identity, of their targets and chromatin modifiers but also affected 
genes commonly modulated by Myc in other cellular contexts.  
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Fig. 11 - Omomyc resets regulation nodes of GSCs. (A) RNA-seq expression 
values of selected genes in BT168FO GSCs along a 48h time course of 
Omomyc induction (n=3). The block on the left represents DUSP family genes. 
The middle block contains transcription factors (TFs): the upper thirteen (from 
ASCL1 to SALL1) are GSC-specific and the remaining ones are oncogenes. 
The genes of the right block are well-known Myc targets, involved in 
proliferation, neurodifferentiation and gliomagenesis. The first column of each 
block represents the average expression (log2 FPKM) in untreated cells (0h) in 
the colour scale illustrated by the lower bar: violet indicates low and blue high 
expression. The other columns depict relative expression versus untreated cells 
(average log2FC) at different times (8 - 48h) of DOX treatment, according to 
the scale shown by the upper bar: red indicates low and green high expression. 
The table in the upper left indicates the GSEA (Gene Set Enrichment Analysis) 
score of 19 GSC-specific transcription factors (NES, normalized enrichment 
score; FDR q-value, False Discovered Rate). (B) Enrichment plots obtained by 
GSEA of RNA-seq data from BT168FO. Left. The set of genes targeted by the 
GSCs core TFs downregulated by Omomyc (Suvà et al., 2014). Middle. A 
dataset of genes upregulated by Myc in cancer cells (Zeller et al., 2003) and 
downregulated by Omomyc in BT168FO cells. Right. Genes downregulated 
B 
C 
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in small cell lung cancers carrying Myc amplification (Kim et al., 2010) and 
upregulated by Omomyc. (C) The tables show enrichment analysis of some 
Myc-regulated gene sets, taken from MSigDB database (Ben-Porath et al., 
2008; Schlosser et al., 2005; Schuhmacher al., 2001; Cowling et al., 2008), and 
of the gene set targeted by the GSC core TFs (Suvà et al., 2014), versus genes 
repressed (left table) or induced (right table) by Omomyc. 
 
5.6 Omomyc decreases the expression of a gene set specifically 
bound by Myc. As stated before, the universal amplifier model 
does not distinguish direct from indirect transcriptional Myc 
responses. Very recently, a signature of 100 most strongly 
downregulated genes, validated as a Myc core gene set and 
conserved in several cancer cell lines, was identified (Muhar et 
al., 2018). These genes were directly activated by Myc and were 
characterized by a strong binding of Myc at their promoters. In 
this view, Myc has the capacity to activate selective 
transcriptional programs.  
We therefore decided to verify the presence of this specific Myc 
signature (102 most downregulated genes from Muhar et al., 
2018) in BT168FO cells and to investigate Omomyc effect on 
gene expression. We found that 91 of 102 genes were expressed 
(FPKM≥1) in uninduced BT168FO cells.  
Thereafter, to unravel whether they were bound by Myc at their 
respective promoters, we defined as Myc promoter-targets all 
genes with RPKM≥0.5 and subdivided them in two groups: 
targets highly bound by Myc (RPKM≥1) and targets weakly 
bound by Myc (0,5<RPKM<1). We found that 75 of 91 genes 
resulted highly bound by Myc, while 11 genes overlapped with 
weakly Myc bound targets set, and only 5 of 91 genes were not 
bound by Myc in BT168FO (Fig. 12 A). Further, we asked 
whether the set of 91 genes was differentially expressed, in the 
presence or absence of Omomyc. To this aim, we performed 
GSEA using all our RNA-seq data. We assessed that 82 of these 
91 genes were significantly repressed in the presence of Omomyc 
(Fig. 12 B, top). We also evaluated how many genes were able to 
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respond to short times of Omomyc induction (4-8h). We found 
that 77% of these 82 genes were significantly repressed by 
Omomyc after 4h of doxycycline treatment and the repression 
persisted along the whole-time course (up to 48h) (Fig. 12 B, 
bottom).  
Therefore, we concluded that 89% (91 of 102) of Myc Muhar 
signature is expressed in GSC cells. 95% (86 of 91) of these genes 
are bound by Myc and Myc could primarily act as a selective 
transcriptional activator, controlling protein and nucleotide 
biosynthesis, ribosome biogenesis factors, key regulators in AMP 
metabolism (MsigDB GO analysis, Fig. 12 C; Muhar et al., 2018). 
This supports the hypothesis that Myc may directly activate 
specific transcriptional programs, which, in turn, may induce the 
expression of other downstream genes, increasing transcripts 
level as secondary effect. 
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Fig. 12 - Omomyc decreases the expression of specific Myc signature. (A) 
Venn diagrams between Myc promoter-targets and Myc Muhar signature 
(Muhar et al. 2018) gene sets. (B) GSEA enrichment profiles of Myc Muhar 
signature gene set using all RNA-seq (0-48h of Omomyc induction) data from 
BT168FO cells (top), and GSEA profiles for each time point of DOX treatment 
B 
C 
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1.37E-20
5.98E-20
4.27E-19
4.68E-17
3.64E-15
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5.22E-14
9.06E-13
1.99E-6
7.05E-6
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6.1E-5
7.57E-5
8.58E-5
1.8E-4
2.5E-4
2.98E-4
8.85E-4
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Gene set name
GO_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS
GO_NUCLEOTIDYLTRANSFERASE_ACTIVITY
GO_RIBOSOMAL_SMALL_SUBUNIT_BIOGENESIS
GO_ORGANOPHOSPHATE_METABOLIC_PROCESS
GO_NUCLEOSIDE_PHOSPHATE_BIOSYNTHETIC_PROCESS
GO_ORGANONITROGEN_COMPOUND_BIOSYNTHETIC_PROCESS
GO_MATURATION_OF_SSU_RRNA
GO_RRNA_METABOLIC_PROCESS
GO_NCRNA_METABOLIC_PROCESS
GO_NCRNA_PROCESSING
GO_RNA_PROCESSING
GO_SNORNA_BINDING
GO_POSITIVE_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC
GO_ORGANONITROGEN_COMPOUND_METABOLIC_PROCESS
GO_RIBOSOMAL_LARGE_SUBUNIT_BIOGENESIS
GO_SMALL_MOLECULE_METABOLIC_PROCESS
GO_RIBOSOME_BIOGENESIS
GO_POLY_A_RNA_BINDING
GO_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS
GO_RNA_BINDING
MsigDB Gene Ontology analysis 
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(4-48h) (bottom). The Myc Muhar gene set is significantly decreased by 
Omomyc (see also orange table). Abbreviations: NES, normalized enrichment 
score; FDR, false discovery rate. (C) MsigDB Gene Ontology analysis on each 
Myc Muhar gene set of A. 
 
5.7 Myc promotes the symmetrical di-methylation of Arginine 
1810 (R1810) residue of RNAPII. Myc regulates many aspects 
of transcription by RNAPII (Rahl et al., 2010) but its role in 
transcript termination is unknown. Recently, it has been reported 
that termination of transcription is regulated by the symmetrical 
di-methylation of RNAPII carboxy-terminal domain (CTD) 
mediated by PRMT5. This modification allows the recruitment of 
proteins like SMN necessary for resolving R-loops in 
transcription termination regions, thus allowing proper 
termination and splicing of transcripts (Zhao et al., 2016). Myc 
and Omomyc functionally interact with PRMT5 (Mongiardi et 
al., 2015). Therefore, we asked whether Myc may regulate 
transcription termination and if Omomyc may interfere with this 
process. To investigate the potential role of Myc in the 
symmetrical di-methylation of R1810-CTD-RNAPII we 
overexpressed Myc transfecting CbS-Flag-Myc construct in 
HEK-293T cells. In parallel, we transfected also Flag-Omomyc 
(CbS-Flag-Omomyc) either alone or in combination with Flag-
Myc. We also performed the same experiment in the presence of 
a short-hairpin RNA for Myc (shMyc). Cell extracts from 
transfected cells underwent several immunoprecipitation 
analyses, to pull down RNAPII using the 8WG16 antibody. We 
found that Myc overexpression induced a significant (p-value 
0,001) symmetrical di-methylation of R1810, whereas Myc 
inhibition by shMyc decreased the di-methylation level (p-value 
0,05) (Fig. 13 A). Omomyc seems to counteract the capacity of 
Myc to promote R1810me2s in co-transfection experiments. 
Surprisingly, Omomyc alone appeared to increase the RNAPII-
R1810me2s level (Fig. 13 A and see also B). We did not observe 
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a coherent increase or decrease of SMN proteins associated with 
RNAPII in parallel to the symmetrical di-methylation of R1810 
(Fig. 13 A). We have also found that Myc and Omomyc co-
immunoprecipitated with RNAPII (Fig. 13 B).  
 
 
 
 
 
 
 
 
 
 
A HEK293T cells 
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Fig. 13 - Myc modulates the symmetrical di-methylation of R1810 on the 
RNAPII CTD. (A) HEK293T cells were transfected with CbS-Flag-Myc, 
CbS-Flag-Omomyc vectors, either alone or in combination, and with CbS-
Flag-Myc/pSLIK-shMyc plasmids. RNAPII was immunoprecipitated using 
the 8WG16 antibody and the symmetrical di-methylation level of R1810 on 
RNAPII CTD was mesaured by immunoblot, using a R1810me2s antibody, 
courtesy of J. F. Greenblatt’s lab, Donnelly Center – University of Toronto, 
Canada. Bottom. The graph shows densitometry of western blots. Each bar 
represents mean±SEM. ***p-value 0,001, *p-value 0,05 repeated measures 
one-way ANOVA. (B) Representative immunoblot of immunoprecipitation 
(IP) experiments from HEK293T cells showing Myc and Omomyc 
immunoprecipitated with RNAPII. 
 
To gain more insights into Myc capacity to promote the 
symmetrical di-methylation of R1810-CTD-RNAPII, we induced 
Omomyc for 24h both in BT168FO and RamosFO cells. By co-
immunoprecipitation experiments, we found that Omomyc 
significantly inhibited R1810me2s in both cell lines (Fig. 14 A 
and B) and Myc and Omomyc co-purify with RNAPII (Fig. 14 
B). The same result was obtained in BT168 cells stably 
transduced with a doxycycline-inducible lentivirus encoding for 
a shRNA for Myc (pSLIK-shMyc, Fig. 14 C). Myc inhibition 
HEK293T cellsB 
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through the shMyc decreased the symmetrical di-methylation of 
R1810, and the association of either PRMT5 or SMN with 
RNAPII (Fig. 14 C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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Fig. 14 - Omomyc or shMyc inhibits the symmetrical di-methylation of 
R1810 residue on the CTD of RNAPII.  Left panel show representative 
immunoblots of IPs from BT168FO (A), RamosFO (B) and BT168shMyc (C) 
cells induced for 24h or 48h, performed using the 8WG16 antibody against 
RNAPII. R1810me2s antibody was used to reveal the symmetrical methylation 
signal of RNAPII on R1810 residue. Each bar represents mean±SEM. ***p-
value 0,001*p-value 0,05 paired t-tests. 
 
5.8 Myc-dependent R1810 symmetrical di-methylation 
requires PRMT5 catalytic activity. PRMT5 associates with 
Myc mediating H4R3me2s) (Mongiardi et al., 2014). Further, 
Myc induces the transcription of prmt5 gene (Koh et al., 2015) 
and R1810me2s modification requires PRMT5 (Zhao et al., 
2016). To verify whether Myc-induced R1810 symmetrical di-
methylation of RNAPII was PRMT5-dependent, we transfected 
HEK293T cells with CbS-Flag-Myc. The day after, transfected 
cells were treated with EPZ015666, a selective inhibitor of 
PRMT5 function, or control vehicle for 24h. Thereafter, 
immunoprecipitation experiments were performed. PRMT5 
catalytic inhibition strongly restrains Myc-dependent R1810 
symmetrical di-methylation of RNAPII (Fig. 15). 
 
 
Fig. 15 – PRMT5 catalytic inhibition restrains Myc-dependent R1810 
symmetrical di-methylation. Immunoblots of immunoprecipitation or input 
HEK293T cells 
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from HEK293T cells transfected with CbS-Flag-Myc and treated or untreated 
with EPZ. H4R3me2s signal (INPUT) confirms the inhibition of PRMT5 
function upon EPZ treatment. EPZ=EPZ015666 
 
5.9 Myc and Omomyc modulate RNAPII carbossi-terminal 
domain (CTD) phosphorylation on Serine 2 (Ser2). Human 
RNAPII CTD contains 52 tandem heptad repeats of the consensus 
sequence Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7. The CTD has 
been demonstrated to play an important role in the transcription 
cycle from initiation to elongation and termination. The transition 
between initiation and productive elongation is elicited by Ser5- 
(Ser5P), followed by the Ser2-CTD-phosphorylation. CTD post-
translational modifications occur during distinct steps of the 
transcription cycle and influence the transcription rate and hence 
mRNAs expression (Phatnani et al., 2006; Buratowski, 2009; 
Rahl al et al., 2010; Koga et al., 2015; Harlen et al., 2016). 
Therefore, we asked whether Omomyc may act on the 
transcription rate, modulating RNAPII phosphorylation on Ser2 
(Ser2P), thus affecting mRNAs expression. First, HEK293T cells 
were transfected with the CbS-Flag-Myc and CbS-Flag-Omomyc 
plasmids, either alone or in combination. The same experiment 
was performed by using the CbS-Flag-Myc construct and the 
pSLIK-shMyc. Immunoblot analyses, using a specific antibody 
against Ser2P-CTD-RNAPII, showed that Myc overexpression 
induces the phosphorylation on Ser2 of RNAPII (Rahl et al., 
2010) (Fig. 16 A). The same result was obtained upon Omomyc 
expression, whereas, in co-tranfection experiments, a reduction of 
Ser2P phosphorylation level was found (Fig. 16 A). In parallel, 
we observed also an increase of CDK9 protein expression either 
when Myc was overexpressed or co-transfected with Omomyc 
(Rahl et al., 2010; Huang et al., 2014). In co-tranfection 
experiments with CbS-Flag-Myc, pSLIK-shMyc strongly 
inhibited Ser2 phosphorylation on RNAPII (Fig. 16A). In 
BT168FO, the Ser2-CTD-RNAPII phosphorylation significantly 
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decreased in the presence of Omomyc (Fig. 16 B). In conclusion, 
consistent with our previous observations, Omomyc expression 
can act on gene expression inducing changes in RNAPII post-
translational modifications and, probably, influencing the 
transcription rate.  
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Fig. 16 - Myc and Omomyc play a role in Ser2 phosphorylation of RNAPII 
CTD. (A) Top. Immunoblots from HEK293T cells transfected with CbS-Flag-
Myc, CbS-Flag-Omomyc and with pSLIK-shMyc vectors, alone or in 
combination showing Ser2P or CDK9 expression levels. Bottom. The graph 
shows the densitometry of the western blot. Each bar represents mean±SEM. 
*p-value 0,05 was determined by repeated measures one-way ANOVA. (B) 
Left. Western blot from BT168FO induced for 24h and depicting Ser2P level. 
Right. Densitometry of the western blot. Each bar represents mean±SEM, *p-
value 0,05 was determined by paired t-test).  
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5.10 Relationship between Omomyc expression, changes in 
RNA Polymerase II distribution at transcriptional start and 
termination sites (TSS and TTS), and changes in gene 
expression. Myc has a relevant role in the symmetrical di-
methylation of R1810 residue (Fig. 13,14,15). Therefore, we 
asked whether Omomyc was able to alter RNAPII amount at 
Transcription Termination Sites (TTSs) versus Transcription 
Start Sites (TSSs). We analyzed ChIP-seq data from BT168FO 
cells. In particular, the RNAPII ratio, calculated as RPKM at 
TTS/ RPKM at TSS, was evaluated (see methods). RPKM values 
from untreated and treated BT168FO cells were normalized by 
their inputs. We analyzed all genes which had a cut-off threshold 
value of FPKM ≥10 in untreated cells.  
For Myc targets, we found that RNAPII ratios in -DOX cells 
versus +DOX cells are anti-correlated: genes showing a higher 
RNAPII ratio in untreated cells decrease this ratio in Omomyc 
expressing cells, while those characterized by a lower RNAPII 
ratio in uninduced cells showed an increase upon DOX treatment 
(Fig. 17 A). The same analysis was performed on non-Myc target 
genes (Fig. 17 B), confirming the finding observed for Myc 
targets (Fig. 17 A).  
 
 
 
 
 
 
 
 
 
A 
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Fig. 17 – Omomyc changes RNAPII occupancy. (A-B) Binned scatter plot 
of genes ranked in ascending order of RNAPII occupancy fold change (FC) 
calculated as RNAPII Occupancy FC = [(TTS /TSS) n°reads (+DOX cells) / (TTS 
/TSS) n°reads (-DOX cells), with FPKM≥10 for comparing relative RNAPII ratio 
from untreated and treated of each bin. 
 
Since Myc promotes symmetrical di-methylation of R1810 on the 
RNAPII CTD and Omomyc counteracts this capacity, we wanted 
to verify whether changes in RNAPII ratio are correlated with 
gene expression. To this end, we calculated the log2RNAPII ratio 
FC and plotted this data against the respective log2FC expression 
(24h) of each gene. We did not find a significant correlation 
between changes in RNAPII ratio and the Omomyc-dependent 
downregulation or upregulation of gene transcription (Fig. 18 A). 
Nevertheless, we decided to investigate whether the modulation 
in gene expression of Muhar Myc target gene set signature and 
GSC regulatory genes by Omomyc was correlated with the 
RNAPII ratio changes observed in the +DOX condition. As 
previously shown, Muhar gene set (Muhar et al. 2018) is a 
B 
Bins (100 genes each) 
Non-Myc targets 
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specific Myc signature also in BT168FO cells. Genes belonging 
to the Muhar gene set are bound at promoters by Myc (Fig. 12) 
and are characterized by an early response to Omomyc induction 
(Fig. 12 B). GSC gene set, instead, includes all those genes related 
to cancer stem cell behavior according to literature data and which 
are significantly modulated by Omomyc in BT168FO cells (Fig. 
11). Most of the genes of Muhar Myc target genes show a higher 
RNAPII amount at TSSs versus TTSs also in the presence of 
Omomyc (Fig. 18 B and C), and increased RNAPII ratio in treated 
versus untreated cells, compared to GSC gene set. Analyzing the 
RNAPII changes at TTS versus TSS regions, we found a strong 
correlation between RNAPII ratio FC changes and the 
downregulation of Muhar Myc target genes, in the presence of 
Omomyc, compared to GSC regulatory genes (Fig. 18 D and E). 
Altogether, these data may suggest that Omomyc, inhibiting the 
RNAPII R1810me2s, may reset the expression of specific Myc 
gene networks through changes in RNAPII distribution on TTS 
versus TSS regions.  
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Fig. 18 – Relation between the gene expression and changes in RNAPII 
ratio upon Omomyc induction.  (A) Dispersion graph displaying the 
correlation between RNAPII FC, calculated as RNAPII RATIO+DOX/RNAPII 
RATIO-DOX, and log2FCexpression 24h from RNA-seq data (3 experiments) of Myc 
Muhar signature and GSC regulatory genes. (B-C) Scatter plots showing the 
relation between log2 RNAPII RATIO (-DOX) and log2 RNAPII RATIO 
(+DOX) of Muhar Myc targets and GSC genes sets. (D-E) Scatter plots 
describing the relation between gene expression (log2FCexpression 24h) and 
RNAPII FC of Muhar Myc and GSC gene sets. 
 
 
5.11 Discussion. The molecular details of the outstanding 
action of Omomyc in cancer are still largely unknown. In the 
present study, we attempted to shed light on the significant impact 
of Omomyc expression in glioblastoma cancer stem cells (GSCs) 
and Burkitt’s lymphoma cells. We found that Omomyc replaces 
Myc on E-box regions around transcription start sites (TSSs) (Fig. 
4). This phenomenon influences also genomic loci bound by Myc 
and other transcription factors (Table 1), suggesting that Myc 
may cooperate with other proteins to regulate subsets of genes 
involved in different aspects of GSCs behavior. We also found 
that Omomyc binds to Myc genomic loci as homodimers (Fig. 5 
C), which are more stable and with higher DNA affinity than 
Myc/Max heterodimers (Savino et al., 2011; Jung et al., 2017). 
Accordingly, we observed a 40-50% reduction of Myc binding at 
promoters upon Omomyc induction. Further, Omomyc 
recruitment seems to be proportional to the amount of bound Myc 
(Fig. 4 and 6 A, B). Consequently, Omomyc occupancy of 
genomic loci, usually bound by Myc/Max heterodimers, may 
influence many processes, such as cancer cells differentiation and 
metabolism (Carroll et al., 2015). The sustained and persistent 
Myc expression contributes to the formation of high number of 
Myc/Max dimers which invade the transcriptional active sites of 
chromatin containing E-box or non-E-box sequences. This makes 
tumor cells addicted to Myc-dependent transcriptional 
amplification (Nie et al., 2012; Lin et al., 2012; Guo et al., 2014; 
Sabò et al., 2014; Wolf et al., 2015).  Max can form stable 
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homodimers even in the presence of Myc and bind DNA with 
comparable affinity to the Myc/Max heterodimer (Wolf et al., 
2015; Maltais et al., 2017). In addition, it has been demonstrated 
that the alternative spliced form of Max provokes an increase in 
overall chromatin-bound Myc, compromising the ability of wild-
type Max/Max complex to attenuate the binding of Myc to 
specific (E-boxes) and non-specific (non-E-boxes) DNA regions 
(Gu et al., 1993; Lindeman et al., 1995; Maltais et al., 2017). 
Moreover, increased Mad/Max and Max/Max dimers formation 
slows down proliferation, committing the cells towards apoptosis 
or differentiation (Eisenman, 1997; Grandori et al., 2000). 
Therefore, by either inducing Max or reducing Myc proteins 
expression, Omomyc may facilitate Max/Mad or Max/Max 
formation, affecting the stoichiometry of Max and Myc molecules 
(Fig 5 B and C). It is known that Myc occupancy is related to the 
expression level of transcripts (Lin et al., 2012; Walz et al., 2014; 
Conacci-Sorrell et al., 2014; Wolf et al., 2015; De Pretis et al., 
2017). Consistently, in GSCs, we observed that highly expressed 
Myc-target genes, which are significantly downregulated by 
Omomyc, show a higher amount of Myc bound at promoters than 
Omomyc upregulated genes (Fig. 6 C). This is in agreement with 
the finding that highly expressed genes - both Myc and non-Myc 
targets - are preferentially downregulated by Omomyc. Less 
expressed genes, instead, may either be similarly upregulated or 
downregulated, while the expression of the vast majority of 
transcripts do not substantially change (Fig. 7 and 8). This is in 
line with the minimal effect on RNAPII loading at TSSs and with 
the decreased transcript amounts only of a subset of targets upon 
loss of Myc binding at promoters (Fig. 10).  
Indeed, Omomyc affects specific gene groups, both Myc and non-
Myc target, in GSCs (Fig. 11 and 12), and regulates multiple gene 
signatures, whose expression is altered by Myc overexpression in 
different types of tumors (Fig. 11 B, C and 12). Taken into 
consideration all these data, we propose the following mechanism 
to explain Omomyc ability to specifically hit cancer features (Fig. 
2 and 3): Omomyc recognizes Myc “invaded”, low affinity 
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promoters and reshapes the Myc interactome, competing with 
Myc/Max heterodimers. This is consistent with the model 
describing Omomyc capacity to sense oncogenic Myc levels at 
weakly or unbound promoters in normal conditions (low affinity 
promoters, Jung et al., 2017). In this way, Omomyc may 
redistribute Myc occupancy on the genome, resetting the Myc-
dependent GSC oncogenic gene expression pattern. Indeed, the 
decrease in Myc binding is not uniform for all promoters (Fig. 4). 
Omomyc homodimers may compete with Myc/Max heterodimers 
more easily at low-affinity sites than at high affinity sites, where 
Myc-Max complexes are stabilized also by protein-protein 
interactions through Myc N-terminal domain, which lacks in 
Omomyc (Guo et al., 2014; Thomas et al., 2015; Lorenzin et al., 
2016; Jung et al., 2017). This may lead to the inhibition of Myc 
transcriptional programs in GSCs (Fig. 11). 
In summary, GSC Myc targets, whose level of expression 
changes upon Omomyc induction, may represent genes under the 
control of low affinity promoters, more sensitive to Myc 
inhibition. On the contrary, genes insensitive to Omomyc 
induction may be controlled by the so-called high affinity 
promoters. In this scenario, it is still debated whether Myc 
globally enhances transcription (amplifier model) or it is a gene 
specific regulator (specifier model) or the transcription 
amplification by Myc is a secondary effect of Myc 
overexpression, due to the occupancy of previously empty 
chromatin loci (Sabò et al., 2014; Lorenzin et al., 2016). At 
strictly controlled normal levels, Myc acts on specific gene sets, 
regulating distinct biological processes. Conversely, when Myc is 
expressed at supraphysiological levels, may boost global gene 
expression, invading promoter and enhancer regions (Wolf et al., 
2015; Nie et al., 2012; Lin et al., 2012; Sabò et al., 2014), with 
different binding affinities (Lorenzin et al., 2016), or chromatin 
sites where the transcription machinery is already active (Guo et 
al., 2014). In this regard, our findings may clarify how Myc 
enhances transcription in cancer cells. High and persistent Myc 
levels tend to saturate weak binding sites, which are normally not 
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bound by Myc, while high-affinity sites are already occupied 
(Lorenzin et al., 2016). The increase of Myc binding to the low 
affinity promoters may induce the amplification of the relative 
genes and in turn downstream targets, promoting an increase in 
total cellular RNA content, as a secondary effect (domino effect) 
(Kress et al., 2015, Muhar et al., 2018). Thus, Omomyc acting on 
key Myc promoter-targets, responsible of GSC behavior (Fig. 11 
and 12), indirectly affects the expression of other downstream 
genes, as a sort of domino effect. In this view, Myc could not act 
as universal amplifier (Lin et al., 2014; Nie et al 2014; Walz et 
al., 2015), but rather as a specifier, that is, it may act on specific 
gene sets, indirectly inducing global changes in RNA and mRNA 
levels (Fig. 7,8,9 and 11 Sabò and Amati, 2014; Kress et al., 2015, 
2016). In support to this hypothesis, in a very recent study, a rapid 
Myc protein degradation was induced and direct changes on 
newly mRNA outputs were measured, to identify Myc direct 
transcriptional targets. A set of genes, conserved in many tumor 
cell lines, was found. These genes were directly activated and 
bound at promoters by Myc, they are, instead, negatively 
modulated by Omomyc (Muhar et al., 2018). We also found that 
the genes belonging to this Myc signature are expressed and the 
corresponding promoters are bound by Myc in GSCs (Fig. 12). 
Therefore, Omomyc may help to unmask Myc function – i.e. the 
transcriptional control of specific gene subgroups – undetectable 
in cancer cells, where Myc overexpression appears to drive a 
genome-wide transcriptional amplification, which may be, 
instead, considered a secondary effect of a gene expression 
cascade. Hence, Omomyc expression may lead to the detachment 
of the excess of Myc from certain key gene promoters, probably 
from low-affinity sites.  
The relative levels of Myc-modulated transcripts appear to be 
rebalanced in the presence of Omomyc: those commonly 
enhanced by Myc are repressed, and vice versa (Fig. 7 and 11). 
This suggests that Myc can act not only as an activator but also as 
a repressor (Sabò et al., 2014; Walz et al., 2014). Although the 
molecular mechanism of Myc transcriptional repression is not 
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totally clear (Loven et al., 2012), many studies report that Myc 
may repress genes through the interaction with Miz-1 (Seoane et 
al. 2001; Staller et al., 2001). Therefore, we may hypothesize that 
Omomyc, interacting with Miz-1 (Savino et al., 2011), may 
weaken Myc-dependent repression. Consequently, several genes 
may result induced by Omomyc (Fig. 7 and 8).  
Based on these considerations, Omomyc appears to be a sensitive 
controller of deregulated Myc levels, both when Myc is bound at 
DNA and when Myc associates to coregulatory proteins, such as 
RNAPI,II and III complexes and their co-factors (Gomez-Roman 
et al., 2003; Arabi et al., 2005; Rahl et al., 2010; Kaur, Cole et al., 
2013; Campbell, White et al., 2014; WB et al., 2015; De Pretis et 
al., 2017). 
Indeed, Myc is involved in many aspects of RNAP II-dependent 
transcription: activation, pause release, elongation (Rahl et al., 
2010). It also affects mRNA splicing, regulating the transcription 
of the core of pre-mRNA splicing machinery, including PRMT5 
(Koh et al., 2015). In this regard, we previously observed that 
PRMT5 functionally interacts with both Myc and Omomyc 
(Mongiardi et al., 2015). PRMT5, in turn, symmetrically di-
methylates RNAPII at R1810, thus allowing proper termination 
and splicing of transcripts (Zhao et al., 2016). Here, for the first 
time, we demonstrate that Myc is also involved in transcription 
termination, both in GSCs and BL cells. 
We found that Myc induces symmetrical di-methylation of R1810 
residue, while Omomyc counteracts this capacity (Fig. 13 and 
14). Both Myc and Omomyc co-purified with RNAPII (Fig. 13 B 
and 14 B). Further, Myc inhibition by RNA interference led to a 
decrease of R1810me2s modification (Fig. 14 C), while PRMT5 
catalytic activity was necessary for Myc-dependent symmetrical 
di-methylation of RNAPII-R1810 (Fig. 15). These data address a 
specific role to Myc in regulating the transcriptional termination 
through the R1810me2s-RNAPII. Furthermore, we observed that 
Omomyc modulates RNAPII amount at TTSs versus TSSs in 
several genes (Fig. 17). In particular, the RNAPII ratio for the 
Muhar Myc signature (Fig. 12, Muhar et al., 2018) is increased in 
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Omomyc expressing cells (Fig. 18 B) compared to GSC 
regulatory genes (Fig.11, Galardi et al., 2016), in which this ratio 
does not significantly change (Fig. 18 C). The correlation 
between RNAPII increase at TTSs and the Omomyc-dependent 
downregulation of Muhar Myc target genes, suggests that the 
PRMT5/Myc/RNAPII-R1810me2s pathway could represent a 
novel molecular axis perturbed by Omomyc, in cell systems 
characterized by Myc overexpression. However, to better clarify 
the specific role of Myc in transcription termination, it would be 
useful to investigate the formation of DNA:RNA hybrid 
structures, called R-loops, which are elongated at pause sites 
downstream of poly(A) signals. R-loops have great physiological 
roles in transcription and chromatin structure and their resolution 
is important for correct termination of transcripts. An 
accumulation of R-loops may lead to genomic instability, splicing 
defects and chromatin alterations, all phenomena frequently 
associated to cancer (Santos-Pereira & Aguilera 2015; Lionel et 
al., 2016). Therefore, Myc-dependent increase of R1810me2s in 
FlagMyc-overexpressing HEK293T cells and in BT168FO cells 
(Fig. 13 and 14) may cause an overload of RNAPII at termination 
sites with the consequent accumulation of R-loops and the 
expression of aberrant transcripts. Omomyc expression, inducing 
a reduction of R1810me2s-RNAPII level, may promote R-loops 
resolution. 
Moreover, Omomyc is able to modulate Ser2 phosphorylation on 
RNAPII CTD (Fig. 16). However, Omomyc seems to counteract 
Myc functions only when Myc is overexpressed (Fig. 14 and 16; 
Soucek et al., 2002), while at low Myc levels (e.g in HEK293T 
cells), Omomyc may not negatively influence Myc activity, but 
may have additional effects (Fig. 13, 16 A). This may be due to 
relevant differences in Myc protein amount expressed in different 
cell systems. Indeed, Myc is very low in HEK293T cells (Fig. 13 
A), while in BT168FO cells is highly expressed (De Bacco et al., 
2012; Fig. 5 C). Since Myc regulates transcription from initiation 
(Rahl et al. 2010) to termination (Fig. 13), we think that these data 
may suggest another mechanism by which Omomyc expression 
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may influence Myc-driven  transcription. Specifically, Omomyc 
may remove the “excess” of Myc from protein complexes 
involved in the transcription process, such as the RNAPII 
transcriptional machinery.  
The involvement of Myc in many steps of RNAPII-mediated 
transcription confirms, at least in part, our hypothesis regarding 
the capacity of Omomyc to recognize deregulated Myc levels in 
cancer cells. Indeed, the gain in Myc binding is correlated with 
the RNAPII recruitment. This leads to an overload of the 
transcriptional machinery at active loci, with a reduction of 
RNAPII elongation and increase of RNAPII amount at gene-
bodies, leading to an accumulation of unprocessed mRNAs (De 
Pretis et al., 2017). Omomyc may revert this condition inhibiting 
RNAPII R1810me2s and Ser2P modifications, normalizing the 
transcript expression levels altered by Myc.  
In this view, Omomyc seems to reset the gene expression of Myc 
target and non-target genes associated with GSCs phenotype 
affecting Myc binding at DNA (Omomyc action model I, see 
below) and maybe disrupting Myc protein-protein interactions 
(Omomyc action model II, see below). In summary, we conclude 
that Myc directly binds and controls specific gene sets, whose 
amplification promotes an increase of transcripts level of 
downstream genes, as a secondary effect (domino effect). This 
consequent transcriptional amplification may depend, at least in 
part, by Myc ability to accelerate the transcription cycle, by acting 
on RNAPII post-transcriptional modifications. Omomyc function 
as a sensitive controller of oncogenic Myc levels in cancer cells 
may also explain how the small peptide expressed in vivo does 
not elicit significant side effects (Soucek et al., 2008). In these 
terms, Omomyc represents both a good tool to elucidate how cells 
lose the control of Myc and a very promising therapeutic strategy 
for inhibiting Myc oncogenic functions (Wang et al., 2018). 
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In brief:  
➢ Omomyc normalizes Myc levels bound at DNA and in 
Myc protein complexes, resetting the gene expression 
altered by Myc overexpression in cancer.  
 
 
 
 
 
Figure modified by Stefan et al., 2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 82 
 
Materials and Methods 
 
Cell culture, proliferation, self-renewal, cell-migration 
assays, and treatments. BT168 Glioblastoma stem cells (GSCs) 
were previously described in De Bacco et al. 2012. Cells were 
grown as neurospheres in serum-free medium, DMEM/F-12 
(SIGMA, St.Louis, Mo, USA) supplemented with B-27™ 
Supplement (50X), 1% penicillin/streptomycin, 2mM 
Glutammine (Thermo Fisher Scientific, Waltham, USA), 10 
ng/mL EGF and bFGF (Life Technologies, Carlsband, CA, 
USA). Cell proliferation was estimated by seeding GSCs in six-
well plates (2 × 104 cells/well) and counting cells daily: the cell 
suspension was thoroughly homogenized with micropipette and 
aliquots of 10 µl were used for counting on a haemocytometer 
(Bright-Line; Hausser Scientific, Horsham, PA, USA) in 
combination with trypan blue dye. Team of two individuals 
counted triplicate samples from three identical sample sets. For 
self-renewal, GSCs were seeded in 96-well plates at 100 
cells/well. The neurospheres number was counted after 7 days 
and plotted against the number of cells seeded; team of two 
individuals counted triplicate samples from three identical sample 
sets.  In vitro migration was assayed by Transwell-96 system (BD 
Bioscience, San Jose, CA). After 24 h, migrated cells were stained 
with crystal violet solubilized with 10% acetic acid and 10 fields 
were counted per assay. Burkitt’s lymphoma Ramos cells were 
characterized by Dalla Favera et al. 1982. Cells were cultured in 
RPMI-1640 medium supplemented with 10% FBS (Thermo 
Fisher Scientific), 1% penicillin/streptomycin, 2mM 
Glutammine. HEK293T cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM, SIGMA), supplemented with 
10% FBS, 2 mM Glutamine and penicillin/streptomycin. 
Cells harbouring a doxycycline inducible Flag-Omomyc (FO) 
were obtained by lentiviral infection. BT168FO and Ramos FO 
cells were treated respectively with 0.25 μg/mL and 0.1 μg/mL 
doxycycline (SIGMA) to induce Omomyc expression. To obtain 
BT168shMyc cells, BT168 cells were transduced with an 
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inducible lentivirus expressing a short hairpin RNA for Myc and 
treated with 0.25 μg/mL doxycycline to induce shMyc. HEK293T 
cells were treated with 5uM EPZ-015666 (1:1000). Cells were 
harvested 48h after treatment and the inhibition of PRMT5 
activity was tested with Immunoblots for H4R3me2s. 
 
Lentiviral infection. The lentiviral plasmid pSLIK-FO was 
constructed by Gateway cloning (Life Technologies). A Flag-
Omomyc insert was amplified by PCR with primers introducing 
5’KpnI and 3’XhoI restriction sites. The KpnI-XhoI fragment was 
purified and cloned in entry vector pEN_TTmcs (courtesy of 
Debbie Burkhart) downstream of TRE-tight promoter. The TRE-
tight promoter/FlagOmomyc construct was subcloned into 
pSLIK-Hygro (Addgene #25737) co-expressing a hygromycin 
resistance gene and Tet-transactivator rtTA3. The lentiviral 
plasmid pSLIK-shMyc (shMyc sequence: 
TGCTGTTGACAGTGAGCGAAAGATGAGGAAGAAATCG
ATGTAGTGAAGCCACAGATGTACATCGATTTCTCCTCA
TCTTCTGCCTACTGCCTCGGA) was engineered cutting 
pSLIK-FO using PacI and SnaBI to cut away Gateway platform. 
The fragment PacI-SnaBI was purified. PCR from GEPIR (all-in-
one shRNA-vector; Fellmann et al., 2013) for TRE3G-EGFP-
mir30E band inserting the SnaBI and PacI sites. The fragment 
TRE3G-EGFP-mir30E was purified and cloned in pSLIK-PacI-
SnaBI vector. pSLIK-SnaBI-mir30E-PacI was cutted with SnaBI 
for re-inserting RRE and Flag sequence. The final vector pSLIK-
shMyc co-express hygromycin resistance gene and Tet-
transactivator rtTA3. Lentiviruses were prepared by co-
transfecting (Lipofectamine 2000 reagent, Thermo Fisher 
Scientific) HEK293T cells with pSLIK-FlagOmomyc and 
packaging plasmids PLP1, PLP2 and pMD VSV-G diluted in 
Opti-MEM (Thermo Fisher Scientific). The medium was 
removed after 12-24h and replaced with 4mL fresh culture 
medium. Supernatants were collected every 24h between 48 to 
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72h after transfection, pulled together and concentrated by 
ultracentrifugation in a Beckman SW-28 rotor for 2h at 25000 
rpm, 4°C.  For infection, 2-5 × 105 cells were seeded in 35mm 
dishes and infected the following day in the presence of 4 µg/mL 
polybrene. BT168FO cells were selected with 50–200 μg/mL 
hygromycin B (SIGMA), and Ramos FO cells with 400-800 
µg/mL. After selection, Flag-Omomyc and shMyc expression 
were assessed by western blots.  
 
RNA isolation and Real Time-PCR. Total RNA was isolated by 
TRIzol (Invitrogen). RNA was reverse-transcribed by M-MLV 
Reverse Transcriptase and random hexamer primers (Invitrogen). 
Real Time-PCR was performed using the SYBR Green select 
master mix (Life Technologies).  
                                           Primers:  
  CCND1: FW gaagatcgtcgccacctg 
                             REV gacctcctcctcgcacttct  
                 SOX2: FW atgggttcggtggtcaagt 
                             REV ggaggaagaggtaaccacagg  
                 PTEN: FW cagccgttcggaggattat 
                             REV ttctcctcagcagccagag  
             NESTIN: FW gaggtggccacgtacaggacc 
                             REV ctgaaagctga gggaagtcttgga 
           NOTCH1: FW gctccttccggctgatttat 
                             REV cttaaccaggcttggcaca. 
              c-MYC:  FW agctgcttagacgctggatt 
                              REV aagttctcctcctcgtcgc 
 
Flow cytometry evaluation. Cell cycle analysis. 5 × 105 Ramos 
cells were centrifuged at 2500 r.p.m for 5 min and washed in 1 
mL PBS. Then, cells were pelleted and fixed by the dropwise 
addition of 500 μL of cold 70% methanol and gently mixing. 
Following 2h fixation at 4°C, the cells were pelleted (2500 rpm 
for 5 min) and washed twice with PBS. Cells were resuspended 
in 1mL PBS-RNAase A 50μg/mL for 30min at 37°C. After that, 
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the cells were pelleted and resuspended in staining buffer – 500 
μl PBS-0,01% Tryton, 10 μl propidium iodide PI (stock solution 
1 mg/mL, SIGMA) - and incubated in the dark at 4°C for 20 min. 
Cells were pelleted, washed twice in PBS (1000 rpm for 5 min), 
and resuspended in 500 μL PBS. For each sample, 10,000 events 
were analyzed using a FACSCalibur cytometer (Becton 
Dickinson, Franklin Lakes, New Jersey, Stati Uniti). Data were 
analyzed with ModFit software (Verity Software House, Inc.) 
Annexin V staining. 5 × 105 Ramos cells were collected, washed 
with PBS and resuspended in 500 μL of 1X binding buffer. 
Annexin V-FITC/PI were added to a final concentration of 1 
mg/mL and the cells were incubated at room temperature in the 
dark for 15 min. A total of 10,000 events were collected per 
sample.  
 
Transfection. Flag-Omomyc (pCbsFlag-Omomyc), Flag-Myc 
(pCbsFlag-Myc), pSLIK-shMyc plasmids were transfected using 
Lipofectamine 2000 (Thermo Fisher Scientific) according to the 
manufacturer’s instructions. Cells were harvested 48h after 
transfection.  
 
Immunoprecipitation. IP was performed with RIPA buffer 
(140mM NaCl, 10mM Tris pH 7.6-8.0, 1% Triton, 0.1% sodium 
deoxycoholate, 1mM EDTA, Zhao et al., 2016) containing 
protease inhibitors (Roche, Basilea, Svizzera) and benzonase 
(SIGMA). 10 to 20 × 106 cells were lysed on ice for 25 minutes 
by vortexing and forcing them through a 27-gauge needle, at least 
10 times, and centrifuged at 13000 rpm for 15 min at 4°C. The 
supernatant was incubated with 10μL-25µL of protein A/G beads 
(Thermo Fisher) and 1-2μg of antibodies for 4h to overnight. The 
samples were washed 3 times with RIPA buffer and boiled in SDS 
gel sample buffer. To detect R1810me2s modification on RNA 
polymerase II (RNAPII), alkaline phosphatase (Roche) treatment 
(5μL) at 37°C for 30 min was performed for RNAPII 
immunoprecipitated samples before boiling.  
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Immunoblotting. Proteins were resolved in 6-8-10 or 12% 
polyacrilammide gels and transferred to PVDF (Bio-Rad, 
Hercules, CA,USA) or nitrocellulose membranes (GE Heath 
Care, Little Chafont, Buckinghamshire, UK) for 2h  at 250 mA 
on ice or over-night at 30V. Filters were blocked in phosphate 
buffered saline plus 0.1% Tween-20 (PBST, SIGMA) added 
with 10% non-fat dry milk, for 1 hour and half at room 
temperature (RT). Primary antibodies were incubated over-
night (O/N) at 4 °C, according to the concentration 
recommended by the manufacturer, in PBST plus 2.5%-5% 
non-fat dry milk. After three 10 minutes washes, filters were 
incubated for 1 hour at RT with either goat-anti rabbit (1:5000) 
or goat-anti mouse (1:2000) horseradish peroxidase (HRP)-
conjugated secondary antibodies (Merck Millipore, Darmstadt, 
Germany). Blots were developed using SuperSignal West Pico 
Chemiluminescent Substrate or Femto Maximum Sensitivity 
(Thermo Fisher Scientific). Images were captured with a 
Chemidoc XRS+ (Bio-Rad, Hercules, CA, USA) and quantified 
using ImageJ software. Anti-Myc (9E10 and N-262), anti-
CDK9, anti-RNAPII (8WG16) antibodies were from Santa 
Cruz Biotechnologies, anti-H4R3me2s, anti-PRMT5 antibodies 
were from Abcam; anti-Flag antibody was from SIGMA. Anti-
R1810me2s was courtesy of J. F. Greenblatt’s lab – University 
of Toronto, Canada (Zhao et al., 2016, Nature). Anti-dimethyl-
Arginine Antibody, symmetric (SYM10) was from Merck. 
Anti-RNA polymerase II CTD repeat YSPTSPS (phospho S2) 
was from Abcam. Anti-β-Actin-peroxidase was from SIGMA.  
 
Chromatin Immunoprecipitation (ChIP), ChIP-seq and 
RNA-seq. Samples for ChIP and ChIP-seq assays were prepared 
and analyzed according to Myers Lab ChIP-seq Protocol v041610 
(http://myers.hudsonalpha.org/documents/) and MAGnify 
Chromatin Immunoprecipitation System protocol (Invitrogen). 
Antibodies used: Myc (sc-764Z, Santa Cruz Biotechnologies), 
Max (c-197X, Santa Cruz), RNAPII (sc-899X, Santa Cruz), 
RNAPII phosphor Ser5 (ab5131, Abcam). RNA Pol II phospho 
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Ser2 (ab24758, Abcam and 3E19, Active Motif), Flag (F1804, 
Sigma). Primers:  
 
NCL FW  gctcagtgactctgtctttcc 
 REV  aagtctcgcgcgattagtg  
miR17-92 FW  gaccacagcagttggagaaa 
 REV  aaagcagcccacagactatt 
HDAC1 FW  ccgactgacggtaggga 
 REV  ccgtcgtagtagtaacagactttc 
DUSP10 FW  aagtgtcacaggcggaatc 
 REV  ccaaaggtgggtgagagaaa 
 
For RNA-seq, 2µg total RNA purified by PureLinkRNA Mini Kit 
(Life Technologies) was used. ChIP-seq and RNA-seq libraries 
were prepared at Istituto di Genomica Applicata (IGA; 
www.appliedgenomics.org/) according to Illumina TruSeq DNA 
and TruSeq RNA Sample Preparation Guides. Samples were 
sequenced through Illumina HiSeq 2000 e 2500.  
 
Bioinformatic analysis. ChIP-seq 50-bp reads were mapped to 
hg19 human reference genome (UCSC Genome Browser) using 
Bowtie (Langmead et al., 2009) version 0.12.7 allowing three 
mismatches; reads with multiple best matches were discarded. 
Peak calling was through MACS (Zhang et al. 2008) 1.4.2 with 
10-4 P-value cut-off. The RefSeq transcript annotation of hg19 
was used for computing intersections between peaks and 
promoters. Binding enrichment to promoters was calculated by 
the normalized number of ChIP-seq reads as Reads Per Million 
(RPM). In case of multiple TSSs, those with the highest 
enrichment were chosen. Motif enrichment analysis was through 
Pscan-ChIP (analysis performed by Giulio Pavesi, University of 
Milan, Zambelli et al., 2013). To calculate the distribution around 
TSSs (heat maps) Seqminer v.1.3.3 was used. The RAP (Zambelli 
et al., 2013) RNA-Seq pipeline Tophat v13 
(https://bioinformatics.cineca.it/rap/) - including quality controls, 
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adaptor trimming and masking of low-quality sequences, tophat2, 
bowtie, and CuffLinks 2.2 - was used to reconstruct the 
transcriptome (hg19 reference) and calculate expression values as 
FPKM (Fragment per Kilobase Million per genes). Methods were 
published in Galardi et al. 2016. Comparisons between Myc, 
Omomyc occupancy with the gene expression (FPKM), were 
performed calculating the average values for groups of 100 genes 
(bins) and correlated by a scatter diagram. The linear regression 
model was used to assess the correlation between transcript levels 
in -DOX versus +DOX cells. RNAPII distribution, at TTS versus 
TSS regions, was evaluated using ChIP-seq data. Density reads, 
counted as RPKM, for each gene, at promoter (1500 nt) and 
termination (4200 nt) regions was calculated dividing the number 
of reads by the total number of reads obtained from each 
sequencing per condition (-DOX and +DOX), and by the length 
of the features. Data were normalized by their INPUT. Gene Set 
Enrichment Analysis (GSEA, 
http://www.broad.mit.edu/gsea/index.html) was used to 
determine whether an a priori defined set of genes shows 
statistical significance, according to the differences between -
DOX and +DOX experimental conditions (phenotypes). In 
details, RNA-Seq dataset file – consisting of experiments 
performed in triplicate for each time point of DOX treatment – 
containing two labeled phenotypes (-DOX and +DOX) were 
prepared in TXT format: -DOX included all 0h time points (1° 
phenotype), while +DOX included from 4h to 48h of DOX 
treatment (2° phenotype). The expression dataset was compared 
with several gene sets either exported from GSEA-MsigDB 
database or homemade. The gene sets contained the gene set 
name and the list of included genes. A gene set file was in GMX 
or GMT format. GSEA software calculated an Enrichment Score 
(ES) describing the degree to which a gene set was 
overrepresented at the extremes (top or bottom) of the entire 
ranked list of data set – where genes are ranked according to the 
expression difference between -DOX and +DOX conditions. The 
Enrichment Score ES was calculated by walking down the list. 
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The value statistically increased when it found genes present in 
the gene set and decreased when genes were not present. The 
magnitude of ES was dependent on the correlation of each gene 
with the phenotype. The proportion of false positives was 
evaluated by calculating False Discovery Rate FDR-q value. 
Statistical analysis. Statistical analyses were performed by using 
the GraphPad Prism version 5.0d (GraphPad, La Jolla, CA, USA) 
and Excel (Microsoft Excel, version 2018). All histograms 
represent the mean ±SEM of data obtained in 3 or more 
independent experiments. Statistical significance was determined 
by one-way repeated-measures ANOVA or paired t-test. The box 
plot p-values were calculated by paired Wilcoxon signed-rank 
tests. Regression lines were estimated using linear regression 
models. For genomic data, differential expression was assessed 
by CuffDiff2, as well as by Fold-Change thresholds, and Gene 
Set Enrichment Analysis (GSEA: www.broadinstitute.org/gsea/) 
subdividing Myc targets and non-Myc targets in groups of 500 
genes.  
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